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against methicillin-resistant Staphylococcus aureus infections”. 
As requested, the manuscript was implemented according to the reviewer’s suggestions and all the 
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the author(s)’s comments is also attached. 
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Reviewer #1: Comments: 
1. The quality of figures should be greatly improved, especially the graphical abstract, Figure 3 and 6.  
We apologize for such an issue. According to the reviewer’s suggestion, the image quality was improved for all 
figures. 
2. In line 159, the section 2.2.1., How many ml of dextran sulfate aqueous solutions were added into the Vm 
solution?  What is the solvent of Vm solution? Water or other organic solvents? When centrifuge the unbound 
Vm, how much is the centrifugal speed? And the centrifugal time also should be provided. 
One ml of dextran sulfate aqueous solution at increasing concentrations was added into 1 ml of vancomycin 
aqueous solution. The centrifugal speed used was 20000 rpm for 15 minutes. The manuscript was 
implemented with such information (Materials&Methods section, par. 2.2.1). 
3. For preparing pre-emulsion containing Epikuron® 200, palmitic acid and PFP, how much g/mg of PFP was 
used? To prepare polymeric NBs, How many ml of dextran sulfate aqueous solution was added into the PFP 
emulsion?  
The amount of PFP and dextran sulfate used for each nanobubble formulation were 500 L  and 350 L, 
respectively. Such information was added in the text (Materials&Methods section, par. 2.2.2). 
4. In line 199, for the TEM observation, the type and brand for the TEM equipment should be provided in the 
text. 
The type and brand of the instrument used for TEM analyses (Philips CM10 (Eindhoven, NL)) were added in the 
text (Materials&Methods section, par. 2.3.1). 
5. To measure the loading capacity, the VmLNBs solution was sonicated and centrifuged, and then the 
supernatant was analyzed. How to validate the VmLNBs were completely broken? Why not use the organic 
solvent to destroy the structure of the VmLNBs? 
The parameters of the used freeze-drying process are severe to maintain the integrity of the nanostructure in 
the absence of any cryoprotectors. Preliminary experiments were carried out to evaluate by optical microscopy 
the nanobubble structure and to set a protocol suitable for determining the loading capacity. The manuscript 
was modified accordingly (Materials&Methods section, par. 2.3.5). 
6. In line 285, the unit of centrifugal speed was g, in line 230, the unit is rpm. The author should check them. 
Some similar expressions also should be uniformed, such as mL and microL. 
All units of centrifugal speed as well as those indicating microliters were uniformed throughout the full text. 
*Response to Reviewers
7.  The viscosity of VmLNBs was higher than that of NB. The reason should be explained in the section of 
"Discussion". Does the change of viscosity affect loading capacity, encapsulation efficiency, physical stability, 
Vm release, and permeation efficiency?   
We apologize for the typing mistake concerning the viscosity value of blank NB formulations. We determined 
again the viscosity using the Ubbelhode capillary viscosimeter to confirm the data. The viscosity of all NB 
formulations (i.e. blank NBs, VmLNBs, fluorescent NBs, and fluorescent VmLNBs) did not show any significant 
changes. A specific sentence was added in the text (Results section par. 3.1). 
8. Table 2 can be incorporated in Table 1. 
According to the reviewer’s suggestion, Table 2 was incorporated in Table1. 
 
Reviewer #2: The development of novel systems for antibiotics is in its infancy as compared to other disease 
conditions and is receiving increasing interest in the literature. Whilst several nanosystems are being reported 
for vancomycin, few, if any have been with nanobubbles. Further, transdermal delivery of nanoencapsulated 
antibiotics is an emerging research area. This paper describes the encapsulation of vancomycin into 
nanobubbles for ultrasound mediated drug release and also to bypass the stratum corneum to optimize the 
treatment of wound infections. This proof of concept study is well designed and the potential of this delivery 
system is demonstrated. The paper is well written with some minor recommendations: 
1. Images of the nanobubbles  show one with a single nanobubble and another with 2. Ideally an image 
showing a population representation should be considered. 
A TEM image showing a population representation of VmLNBs was added in the Supplementary Information.  
2. There are several inconsistencies in the referencing style which need to be corrected. 
All the references were modified according to the journal’s author guidelines. 
3. Pg 18, Line 368. The last sentence is incorrect and needs to be rewritten. 
According to the reviewer’s suggestion, we changed the sentence as follows: “As shown in Figure 3, the drug 
resulted much more stable from a chemical point of view when properly incorporated in the nanocarrier 
(VmLNBs) than as such in solution.”  (Results section, par. 3.2) 
 
Reviewer #3: Manuscript IJP-D-16-02774 "Vancomycin - loaded nanobubbles: a new platform for controlled...." 
by Argenziano et al. describes the fabrication, characterization and release capability of polymer shelled 
droplets loaded with vancomycin. 
The manuscript should be implemented according to the following comments: 
1) It should be specified whether PFP is liquid.  
Perfluoropentane is a perfluorocarbon with a boiling point of 29°C, hence liquid at room temperature. The use 
of PFP allows liquid droplet generation at room temperature. Then, PFP in nanodroplets can be activated by an 
external stimulus, like ultrasound, by means of a mechanism called acoustic droplet vaporization, causing the 
droplet to become a bubble. The sentence was added in the manuscript (Introduction section, lines 117-120). 
2) Term "nanobubbles" can be misleading. At room temperature the core of the particles is liquid PFP. 
Therefore nanobubbles does not describes correctly such particles. It would be more proper the term 
"nanodroplets" or "nanovescicles" 
The formulation is referred to as “nanobubbles” for sake of simplicity (to distinguish them from so-called 
decafluoropentane-containing nanodroplets, already patented by our group; see Introduction section for more 
details about those nanodroplets) but we acknowledge that, prior to the application of ultrasound, it would be 
more precise to use the term “nanodroplets” when the core is constituted of perfluoropentane. This 
clarification was included in the text (Introduction section, lines 129-132). 
3) Figures are not numbered and are very low in resolution (including the graphical abstract). Sometimes 
they are not readable.  
We apologize for the low quality of figures. According to the reviewer’s suggestion, the resolution of all figures  
was improved. Also, Figures were numbered in accordance to legend numbers. 
4) Scheme of the particle differs from the particle description of the graphical abstract in the position of 
vancomycin, tethered to the external surface of the particle and in the particle shell, respectively.  
Vancomycin is included in the polysaccharide shell. For clarity, we modified Figure 1. 
5) Viscosity measurements obtained by capillary viscosimetry should be defined. With an Ubbelhode 
capillary viscometer a relative viscosity, a specific viscosity, an intrinsic viscosity can be obtained. Which one is 
reported ? All of them have different dimensions from the reported one, i.e. cP. Relative (to solvent) and 
specific viscosities are dimensionless, intrinsic viscosity has dimension of an inverse of concentration.  
With the Ubbelhode capillary viscometer, the time required for the nanosuspension to flow through a capillary 
of a known diameter of a certain factor (K) between two marked points was measured. By multiplying the time 
taken, by the factor of the viscometer (0.105), the kinematic viscosity was obtained. The dynamic viscosity was 
obtained by multiplying  kinematic viscosity by density. The cP is the unit of dynamic viscosity in the metric CGS 
(centimeter-gram-second) system. 
6) Vancomycin permeation study puzzled me a lot. The experiment should be conducted at osmotic 
conditions. To avoid Donnan effects with a charged not diffusible solute, i.e. nanobubbles, a suitable diffusible 
ionic strength should be used on both the compartments separated by the membrane. According to the given 
description NaCl 0.9 % w/w has been added only on one compartment. In this conditions other, not controlled 
contributions affects the diffusion process of vancomycin. In the description of the set up, the concentration of 
nanobubbles is not reported.  
We apologize for the inaccurate description of the experimental setup. For in vitro permeation studies, NB 
samples were prepared in saline solution (NaCl 0.9% w/v).  The concentration of NBs in the donor phase was  
1x1012 NBs/ml. All information was added to the text (Materials&Methods section, par. 2.2.2 and 2.5). 
7) When ultrasound are applied, it is important to check the behaviour of the "nanobubbles" 
(nanodroplets) in order to frame the enhanced release. Do "nanobubbles" (naonodroplets) undergo acoustic 
droplet vaporization? This effect is known to transform droplets into bubbles, thus changing the release of the 
payload. 
Nanobubbles were observed by US standard imaging (MyLab ESAOTE instrument) and they showed a good 
scattering response, either in the absence or presence of vancomycin. Further investigations are needed to 
check whether actual vaporization occurred. With regard to the drug release, preliminary experiments showed 
an enhanced release kinetics after US application. 
8) Pg 6 line 115: PFP is liquid or gas ? 
Perfluoropentane is liquid at room temperature, having a boiling point of about 29 °C.  Therefore, it is gaseous 
at body temperature (37°C) as such. 
9) Pg 15 line 332: why in confocal microscopy imaging, bacteria are dried ? 
The drying of bacteria is a step necessary for their staining. After smearing of bacteria on the glass-slide, every 
staining procedure considers that bacteria have to be air-dried to fix them on the slide and to avoid the 
subsequent rinsing of the smear during staining procedure, as well as to allow the sample to more readily take 
up stain(s). 
10) Vancomycin hydrochloride is not mentioned in the Material section. 
Vancomycin hydrochloride was from Sigma-Aldrich (St Louis, MO). Therefore, it falls into the general 
sentence “All materials were from Sigma-Aldrich, St Louis, MO, unless those indicated as follows” 
(first sentence of par. 2.1 in Materials&Methods section). 
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Vancomycin (Vm) currently represents the gold standard against methicillin-resistant Staphylococcus 25 
aureus (MRSA) infections. However, it is associated with low oral bioavailability, formulation stability 26 
issues, and severe side effects upon systemic administration. These drawbacks could be overcome by 27 
Vm topical administration if properly encapsulated in a nanocarrier. Intriguingly, nanobubbles (NBs) 28 
are responsive to physical external stimuli such as ultrasound (US), promoting drug delivery. In this 29 
work, perfluoropentane (PFP)-cored NBs were loaded with Vm by coupling to the outer dextran sulfate 30 
shell. Vm-loaded NBs (VmLNBs) displayed ~300 nm sizes, anionic surfaces and good drug 31 
encapsulation efficiency. In vitro, VmLNBs showed prolonged drug release kinetics, not accompanied 32 
by cytotoxicity on human keratinocytes. Interestingly, VmLNBs were generally more effective than 33 
Vm alone in MRSA killing, with VmLNB antibacterial activity being more sustained over time as a 34 
result of prolonged drug release profile. Besides, VmLNBs were not internalized by staphylococci, 35 
opposite to Vm solution. Further US association promoted drug delivery from VmLNBs through an in 36 
vitro model of porcine skin. Taken together, these results support the hypothesis that proper Vm 37 
encapsulation in US-responsive NBs might be a promising strategy for the topical treatment of MRSA 38 
wound infections. 39 
 40 
Key words 41 








1. Introduction 47 
 48 
Chronic wounds fail to proceed through timely regulated and interrelated processes to restore 49 
anatomical and functional integrity of the injured tissues (Lazarus et al., 1994) such as diabetic feet, 50 
bedsores, and venous ulcers (Markova et al., 2012). To date, these types of wounds are considered like 51 
a silent epidemic, affecting a large fraction of the world population and posing a major gathering threat 52 
to the public health and economy of all developed countries (Daeschlein, 2013). Hospitalized patients 53 
are at particular risk, especially those suffering from diabetes, human immunodeficiency virus or other 54 
immune disorders, as well as those undergoing chemotherapy (Payne et al., 2008).  55 
Beyond delayed healing processes due to different factors (hypoxia, persistent inflammation, and 56 
altered balances between tissue remodelling proteinases and their inhibitors), chronic wounds are often 57 
worsened by microbial infections (Gurusamy et al., 2013). Among the bacteria responsible for skin 58 
infection, Staphylococcus aureus represents the most common pathogen to be identified in chronic 59 
wounds, with methicillin-resistant S. aureus (MRSA) accounting for upward of 20% to 50% of cases 60 
(Price, 2010). MRSA colonies often develop at the interface between synthetic prostheses and 61 
biological tissues, particularly during surgery and post-surgery course. In addition, MRSA colonization 62 
or infection of wounds can result in MRSA bacteremia, which is associated with a 30-day mortality of 63 
about 28% to 38% patients (Gurusamy et al., 2013).  64 
The main goal of chronic wound treatment is to decrease the injuring-associated microbial load, thus 65 
allowing wound healing processes to take place. However, conventional systemic delivery of 66 
antibiotics not only entails poor penetration into ischemic and necrotic tissues, but can also cause 67 
systemic toxicity with associated renal and liver complications, resulting in forced hospitalization for 68 
further monitoring and advanced treatment. On the contrary, topically applied antimicrobials have 69 




alternative local delivery of antimicrobials - either by topical administration or through novel delivery 71 
devices - may enable to keep high local antibiotic concentrations for prolonged release times without 72 
reaching systemic toxicity (                   2008).  73 
A promising approach to develop a topical therapy for microbial infection in skin and soft tissues 74 
would employ biocompatible nanomaterials and drug nanocarriers. Indeed, nanotechnology represents 75 
an emerging field to be exploited for antibiotic drug delivery. Thanks to their physical and chemical 76 
properties (small size, high surface-to-volume ratio and suitable surface modification) nano-sized 77 
materials may be used as drug carriers to trespass several physiological barriers and to reach biological 78 
targets. The coupling of nanocarriers with anti-infectious agents makes it likely to increase drug 79 
concentrations and drug penetration at the site of infection. As a result, it might not only improve the 80 
therapeutic index but also reduce some issues associated with nonspecific cytotoxicity and antibiotic 81 
resistance (Sharma et al., 2012).  82 
Vancomycin hydrochloride, being effective against many Gram-positive bacteria that are unresponsive 83 
to common antibiotics, represents the gold standard against MRSA infections (Kullar et al., 2016). 84 
However, Vm is poorly absorbed from the gastrointestinal tract with a low oral bioavailabiliy. Low 85 
intravenous infusion is often suggested as a feasible alternative for drug administration, but Vm 86 
instability in aqueous solutions at 37°C could imply a tremendous reduction of drug effectiveness 87 
(Mawhinney et al., 1992; Raverdy et al., 2013). Following parenteral administration, Vm displays a 88 
slow mode of action, a complex concentration-time profile, and a disappointingly low penetration in 89 
tissues  (Vandecasteele et al., 2012). Furthermore, systemic Vm administration can be associated with 90 
several adverse effects (Vidal et al., 1992). On the other hand, Vm topical application – that would be 91 
much safer than systemic administration - is currently limited by several factors such as skin barrier 92 
properties and poor drug permeability (Giandalia et al., 2001). Being the main goal of chronic wound 93 




protocol should be devised, since conventional systemic delivery of antibiotics requires a drug 95 
concentration which is locally ineffective because of the poor penetration into ischemic and necrotic 96 
tissues, but can cause systemic toxicity and topically applied antimicrobials have proven effective in 97 
decreasing bacterial levels in granulating wounds (Diehr et al., 2007), without inducing          98 
                             2008) but suffer from poor diffusion across membranes. 99 
Intriguingly, the use of a nanocarrier may help to avoid the abovementioned drawbacks. Notably, 100 
nanocarriers such as liposomes, microemulsions, and lipid nanoparticles have the potential to deliver 101 
drugs to the skin more efficiently than conventional topical carriers such as creams and ointments, that 102 
are not usually recommended for applications on injured skin (Giandalia et al., 2001; Prabhu et al., 103 
2012). However, the response to drug topical applications has been too weak so far, mainly due to the 104 
inability to cross the external skin barrier (stratum corneum) and reach the dermal regions where the 105 
bacteria are nested. Interestingly, physical media such as ultrasound (US) are reportedly able to trigger 106 
drug release at the site of infection by temporarily increasing skin permeability through sonophoresis. 107 
As such, US is useful to promote drug targeting and transdermal delivery in a non-invasive manner 108 
(Azagury et al., 2014; Park et al, 2012).  109 
Microbubbles (MBs) (Guiot et al., 2006), nanobubbles (NBs) (Cavalli et al., 2009a; Cavalli et al., 110 
2009b; Cavalli et al., 2016) and nanodroplets (NDs) (Magnetto et al., 2014; Prato et al., 2015) are 111 
suitable carriers to be combined with such a physical trigger. They are spherical core-shell structures 112 
filled with gases such as perfluorocarbons. Particularly, oxygen-cored nanostructures  can be employed 113 
both for sonography (as contrast agents) (Fokong et al., 2012; Marxer et al., 2011) and for therapy (as 114 
hypoxia- and infection-counteracting devices) (Gulino et al., 2015; Banche et al., 2015; Khadjavi et al., 115 
2015; Basilico et al., 2015; Prato et al., 2016). In particular NBs, consisting in an outer shell of a 116 
biocompatible/biodegradable polysaccharide (chitosan, dextran, or dextran sulfate) and an inner core 117 




a new non-invasive, low-cost and multipurpose nanotechnological platform (Cavalli et al., 2009a; 119 
Cavalli et al., 2009b; Cavalli et al., 2016). PFP is a perfluorocarbon with a boiling point of 29°C, hence 120 
liquid at room temperature. The use of PFP allows liquid droplet generation at room temperature. Then, 121 
PFP in nanodroplets can be activated by an external stimulus, like US, by means of a mechanism called 122 
acoustic droplet vaporization, causing the droplet to become a bubble. Depending on the properties of 123 
the nanostructure, NBs can be subsequently coupled with different molecules, such as drugs or genetic 124 
materials, thus acting as nanocarriers (Cavalli et al., 2012; Cavalli et al., 2013; Delalande et al., 2012; 125 
Yin et al., 2014). Due to their structure and their gaseous core, NBs are very responsive to US and can 126 
take advantage from a number of effects related to microcavitation and microstreaming, occurring at 127 
the liquid-membrane interface and responsible for transitory and reversible openings of the pores, thus 128 
crossing the membrane itself and delivering their content beyond the tissue (sonophoresis) or the cell 129 
(sonoporation) membrane (Karshafian et al., 2009).  130 
Based on these preconditions, the present work aimed at producing dextran sulfate-shelled and PFP-131 
cored NBs for Vm local delivery to potentially treat skin infectious diseases. The formulation is 132 
  f    d       “     u     ” f     k   f    p        u      u        id that, prior to the application of 133 
US, it would be more accurate    u    h       “    d  p    ” wh    h                 u  d  f PFP. 134 
Therefore, Vm-loaded NBs (VmLNBs) were prepared and characterized for physico-chemical 135 
parameters and drug release kinetics; tested for biocompatibility with human skin cells and for their 136 
antibacterial properties or interactions with MRSA; and challenged for responsiveness to US, in order 137 





2. Material and methods 140 
 141 
2.1. Materials  142 
All materials were from Sigma-Aldrich, St Louis, MO, unless those indicated as follows. Sterile 143 
plastics were from Costar, Cambridge, UK; ethanol (96%) was from Carlo Erba (Milan, Italy); soybean 144 
lecithin (Epikuron 200
®
) was from Cargill (Hamburg, Germany); 1-800 Millipore system to obtain 145 
ultrapure water and Amicon
®
 Ultra-0.5 centrifugal filter device were from Millipore (Molsheim, 146 
France); Ultra-Turrax SG215 homogenizer was from IKA (Staufen, Germany); RPMI 1640 medium 147 
was from Invitrogen (Carlsbad, CA); Nanobrook 90Plus Particle Size Analyzer was from Brookhaven 148 
(New York City, NY); Philips CM10 electron microscope was from Philips (Eindhoven, the 149 
Netherlands); Ubbelhode capillary viscosimeter was from SCHOTT Instruments GmbH (Mainz, 150 
Germany); Perkin Elmer PUMP 250B was from Perkin Elmer (Waltham, MA); Flexar UV/Vis LC 151 
spectrophotometer detector was from Perkin Elmer (Waltham, MA); Agilent TC C18 columns were 152 
from Agilent (Santa Clara, CA); Orion Model 420A pH Meter was from Thermo Scientific (Waltham, 153 
MA); Semi-Micro Osmometer K-7400 was from Knauer (Berlin, Germany); Beckman Coulter Allegra 154 
64R Centrifuge was from Beckman Coulter (Brea, CA); Spectra/Por cellulose membranes were from 155 
Spectrum Laboratories  (Rancho Dominguez, CA); HaCaT cells were from Cell Line Service GmbH 156 
 Epp  h     G      );       u  u   RPMI 1640   d Du      ’    d f  d E g  ’    d u   DMEM) 157 
were from Invitrogen (Carlsbad, CA); streptomycin was from Cambrex Bio Science (Vervies, 158 
Belgium); humidified CO2/air-incubator was from Thermo Fisher Scientific Inc. (Waltham, MA); 159 
tryptic soy broth (TSB) and tryptic soy agar (TSA) were from Merk KgaA (Darmstadt, Germany); 160 
Olympus Fluoview 200 laser scanning confocal system mounted on an inverted IX70 Olympus 161 
microscope was from Olympus America Inc. (Melville, NY, USA) ; SPSS 16.0 software was from 162 




2.2. Development and manufacturing of formulations  164 
 165 
2.2.1. Determination of Vm and dextran sulfate interaction ratio 166 
Increasing concentrations (0.25, 0.5, 1.0, 2.0 mg/mL) of dextran sulfate aqueous solutions (1 mL) were 167 
added to 1 mL of Vm aqueous solution (1 mg/mL) under magnetic stirring at room temperature 168 
overnight. After equilibration, the systems were separated by centrifugation (20000 rpm, 15 minutes) 169 
using a centrifugal filter device (Amicon
®
 Ultra), in order to determine the amount of unbound Vm in 170 
the filtrate phase. The drug concentration in the filtrate was determined using the HPLC method 171 
described below. 172 
 173 
2.2.2. Preparation of NB, Vm, and VmLNB formulations 174 
NBs were formulated using PFP for the inner core and dextran sulfate for the shell. A purposely tuned 175 
multi-step protocol was designed. Briefly, a pre-emulsion was obtained adding 300 L of an ethanol 176 
solution containing Epikuron
®
 200 and palmitic acid (1% w/v) to 500 L of PFP under magnetic 177 
stirring. After the addition of 4.8 mL of ultrapure water, the system was homogenized using a Ultra-178 
Turrax SG215 homogenizer. To obtain the polymeric NBs, 350 L of 1% w/v dextran sulfate 179 
(molecular weight = 100 kDa) aqueous solution was added drop-wise under magnetic stirring. Blank 180 
NBs obtained according to this procedure were employed as control formulations in the subsequent 181 
experiments. On the other hand, to obtain VmLNBs, an extra step based on drop-wise addition of a Vm 182 
aqueous solution (pH 3.5) to the so-formed NBs was performed under mild stirring. Different 183 
concentrations of Vm solutions were added to prepare a series of VmLNB formulations with increasing 184 
drug content (0.004, 0.01, 0.1, and 1 mg/mL). VmLNBs were then purified by dialysis to eliminate 185 




addition of 6-coumarin (1 mg/mL) to the PFP core. Alternatively, fluorescent Vm was synthesized 187 
through reaction between fluorescein isothiocyanate (FITC) and Vm. For this purpose, an amount of 188 
FITC solution in methanol (0.2 % w/v) was added to Vm aqueous solution and incubated under stirring 189 
overnight in the dark. Figure 1 shows a representative scheme resuming the general structure of 190 
fluorescent VmLNBs. For cell experiments, NBs were prepared in phosphate buffer saline pH 7.4 191 
(PBS). For in vitro permeation studies, NBs were prepared in saline solution (NaCl 0.9% w/v). 192 
 193 
2.2.3. NB sterilization 194 
Firstly, the glassware and the components were sterilized at 121 °C and 2 bar. Subsequently, all NB 195 
formulations were sterilized through UV-C exposure for 20 min. Thereafter, UV-C-treated materials 196 
were incubated with cell culture RPMI 1640 medium in a humidified CO2/air-incubator at 37°C up to 197 
72 h, not displaying any signs of microbial contamination when checked by optical microscopy.  198 
 199 
2.3. Characterization of formulations 200 
 201 
2.3.1. Characterization of NB and VmLNB formulations 202 
The average diameter, polydispersity index and zeta potential were determined by photocorrelation 203 
spectroscopy using a particle size analyzer at a scattering angle of 90° and a temperature of 25 °C. NB 204 
suspensions were diluted in deionized filtered water before measurement. For zeta potential 205 
determination, samples of diluted NB formulations were placed in the electrophoretic cell, where an 206 
electric field of approximately 15 V/cm was applied. The morphology of formulations was evaluated 207 
by Transmission Electron Microscopy (TEM), using a Philips CM10 (Eindhoven, NL) instrument. NB 208 




observation. The viscosity of the samples was determined at 25 °C using a Ubbelhode capillary 210 
viscosimeter. 211 
 212 
2.3.2. HPLC quantitative Vm determination  213 
Vm quantitative determination was carried out by using an HPLC system based on a Perkin Elmer 214 
pump equipped with a spectrophotometer detector. Analyses were performed using an Agilent TC C18 215 
column (250 mm × 4.6 mm, 5 µm). The mobile phase was a mixture of KH2PO4 50 mM (pH 4) and 216 
acetonitrile (92:8 v/v), degassed and pumped through the column with a flow rate of 1 mL/min. 217 
Ultraviolet detection was set at 286 nm. The external standard method was used to calculate the drug 218 
concentration. For this purpose, 1 mg of Vm was weighted, placed in a volumetric flask, and dissolved 219 
in water to obtain a stock standard solution. This solution was then diluted using the mobile phase, 220 
providing a series of calibration solutions, subsequently injected into the HPLC system. Linear 221 
calibration curve was obtained over the concentration range of 0.5−25 μg/mL, with a regression 222 
coefficient of 0.999. 223 
 224 
2.3.3. In vitro evaluation of Vm stability 225 
Vm chemical stability - either solved in aqueous solution or loaded in VmLNBs - was evaluated at 226 
room temperature and at 37 °C over time. A quantitative determination of Vm concentration over time 227 
was carried out using the HPLC method described above.  228 
 229 
2.3.4. NB stability over time and after US administration 230 
The physical stability of NBs was evaluated by morphological analysis and by size and zeta potential 231 
determination of formulation over time. Their average diameters, zeta potential values and morphology 232 




0.1 MHz; t = 10 min; P = 5 W). NB morphology was observed by TEM to confirm the integrity of NB 234 
structure. 235 
  236 
2.3.5. Encapsulation efficiency and loading capacity of Vm in NBs 237 
The encapsulation efficiency of VmLNBs was determined using a centrifugal filter system. 150 L of 238 
VmLNB suspension were put in an Amicon
®
 Ultra-0.5 centrifugal filter device and centrifuged at 239 
15000 rpm for 30 minutes using Beckman Coulter Allegra 64R Centrifuge. The solution filtered in the 240 
bottom of the tube was quantified and after suitable dilution was analyzed by HPLC, in order to obtain 241 
the concentration of free Vm in VmLNBs suspensions. The encapsulation efficiency was calculated by 242 
subtracting the amount of free drug from the initial amount of added Vm, according to the following 243 
equation:  244 
 245 
The loading capacity was determined on freeze-dried NB samples. Briefly, a weighted amount of 246 
freeze-dried VmLNBs was suspended in 10 mL of water. After sonication and centrifugation, the 247 
supernatant was diluted with mobile phase and analyzed by HPLC. The loading capacity of Vm in 248 
VmLNBs was calculated as follows: 249 
 250 
 251 
2.4. In vitro release studies 252 
In vitro drug release experiments were conducted in a multi-compartment rotating cell, comprising a 253 
donor chamber separated by a cellulose membrane (cut-off = 12000 Da) from a receiving compartment. 254 




in the donor chamber. The in vitro release kinetics of Vm from VmLNB was compared to a Vm 256 
aqueous solution (1 mg/mL) as a control. The receiving phase, containing phosphate buffer 0.05 M (pH 257 
7.4) was withdrawn at regular intervals and replaced with the same amount of fresh buffer. Quantitative 258 
determination of Vm in the withdrawn samples was carried out by the HPLC method, as described in 259 
the previous paragraph. Data were expressed as % of Vm released over time.  260 
 261 
2.5. In vitro permeation study  262 
In vitro studies were performed using a vertical diffusion Franz cell to evaluate Vm permeation 263 
throughout the skin. The Franz cell consists of a donor compartment, with Vm (1 mg/mL, either free or 264 
carried by VmLNBs, 1x10
12
 NBs/ml) and a receiving compartment containing 0.9% w/w NaCl saline 265 
solution. To simulate the stratum corneum properties a membrane pig ear skin was used. Skin slices 266 
were isolated with a dermatome from the outer side of pig ears, obtained from a local slaughterhouse, 267 
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% w/w saline solution, in the presence of 0.01% sodium azide to preserve the skin, at 25 °C for 30 min. 269 
Then, after washing with saline solution, the skin layer was inserted between the two compartments of 270 
the Franz cell, with the stratum corneum side facing towards the donor chamber. The study was carried 271 
out for 24 hours and the receiving phase was withdrawn at regular times and replaced with the same 272 
amount of fresh receiving medium. The collected samples were then analyzed by HPLC to determine 273 
the amount of Vm permeated over time. US abilities to promote Vm permeation were also investigated. 274 
For this purpose, a high frequency US transducer (f = 2.5 MHz; P = 5 W; t = 10 min) was combined to 275 
a purposely modified vertical diffusion cell. Drug permeation through pig skin after US application was 276 






2.6. Human biocompatibility studies 280 
 281 
2.6.1. Human keratinocyte cell cultures 282 
HaCaT, a long-term cell line of human keratinocytes immortalized from a 62-year old Caucasian male 283 
donor (Boukamp et al., 1988), was used for the assessment of Vm and VmLNB biocompatibility. Cells 284 
were grown as adherent monolayers in DMEM medium supplemented with 10% fetal bovine serum, 285 
100 U/mL penicillin, 100 µg/mL streptomycin and 2 mM L-glutamine in a humidified CO2/air-286 
incubator at 37°C. Before starting the experiments, cells were washed with PBS, detached with 287 
trypsin/ethylenediaminetetraacetic acid (0.05/0.02 % v/v), washed with fresh medium and plated at a 288 
standard density (10
6
 cells/well in 6-well plates) in 2 mL of fresh medium. 289 
 290 
2.6.2. Vm and VmLNB cytotoxicity 291 
The potential cytotoxic effects of VmLNBs were measured as the release of lactate dehydrogenase 292 
(LDH) from HaCaT cells into the extracellular medium. Briefly, cells were incubated in DMEM 293 
medium for 24 h with/without 1 mg/mL Vm, either free or carried by VmLNBs, in a humidified 294 
CO2/air-incubator at 37°C. Then, 1 mL of cell supernatants was collected and centrifuged at 12000 rpm 295 
for 2 min. Cells were washed with fresh medium, detached with trypsin/ethylenediaminetetraacetic acid 296 
(0.05/0.02 % v/v), washed with PBS, resuspended in 1 mL of TRAP (82.3 mM triethanolamine, pH 297 
7.6), and sonicated on ice with a 10 s burst. 5 L of cell lysates and 50 L of cell supernatants were 298 
diluted with TRAP and supplemented with 0.5 mM sodium pyruvate and 0.25 mM NADH (300 L as a 299 
final volume) to start the reaction. The reaction was followed measuring the absorbance at 340 nm (37 300 




expressed as μmol of oxidized NADH/min/well. Finally, cytotoxicity was calculated as the net ratio 302 
between extracellular and total (intracellular + extracellular) LDH activities. 303 
 304 
2.6.3. Human keratinocyte cell viability 305 
Cell viability was evaluated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 306 
(MTT) assay. HaCaT cells were incubated for 24 h with/without 1 mg/mL Vm, either free or carried by 307 
VmLNBs, in a humidified CO2/air-incubator at 37°C. Thereafter, 20 L of 5 mg/mL MTT in PBS were 308 
added to cells for 3 additional hours at 37 °C. The plates were then centrifuged, the supernatants 309 
discarded and the dark blue formazan crystals dissolved using 100 μL of lysis buffer containing 20 % 310 
(w/v) sodium dodecyl sulfate, 40 % N,N-dimethylformamide (pH 4.7 in 80 % acetic acid). The plates 311 
were then read on Synergy HT microplate reader at a test wavelength of 550 nm and at a reference 312 
wavelength of 650 nm. 313 
 314 
2.7. Microbiological assays 315 
 316 
2.7.1. Determination of vancomycin antimicrobial activity against MRSA 317 
Vm solutions were freshly prepared for each experiment. Determination of the minimum inhibitory 318 
concentration (MIC) of vancomycin was carried by the microdilution broth method according to the 319 
latest Clinical and Laboratory Standards Institute (CLSI) guidelines (CLSI 2012). Interpretation of the 320 
results was performed as outlined in the above mentioned CLSI guidelines (CLSI 2012). 321 
 322 
2.7.2. In vitro antibacterial efficiency of VmLNBs against MRSA.  323 
MRSA, isolated from human ulcerated wounds (Infermi Hospital, Biella, Italy), was cultured over 324 




min centrifugation at 4,000 rpm, diluted in TSB to 10
4
 colony-forming-unit (CFU)/mL, as confirmed 326 
by colony counts on TSA, and then incubated in TSB with VmLNBs, loaded with Vm at different 327 
concentrations (1, 0.1, 0.01, and 0.004 mg/mL), in sterile sampling tubes for 2, 3, 4, 6, and 24 hours at 328 
37°C. Controls represented by either bacteria incubated in TSB, bacteria incubated with blank NBs or 329 
bacteria incubated in the presence of free Vm at different concentrations (1, 0.1, 0.01 and 0.004 330 
mg/mL), were also performed. At each incubation time, serial 10-fold dilutions in saline solution (0.9% 331 
NaCl) were prepared from each sample, and 100 L of each dilution were spread on TSA, so that the 332 
number of CFU/mL could be determined. 333 
 334 
2.7.3. Imaging with confocal laser scanning microscopy 335 
MRSA bacteria  were grown in TSB at 37°C in agitation until reaching the concentration of 1x10^
9
 336 
CFU/mL. Then, 1 mL aliquot of bacteria was pelleted (3000g x 10 min at 4°C), resuspended in PBS 1x 337 
and incubated with 6-coumarin-labeled VmLNBs, 6-coumarin-labeled NBs, or FITC-labeled Vm at a 338 
dilution of 1:11, as for previous experiments performed on eukaryotic cells. Each sample was placed on 339 
orbital shaker (160 rpm) in the dark at 37°C for 2h and 4h. After incubation, one drop from each 340 
suspension was streaked on poly-L-lysine-coated microscope slides and allowed to dry. Then, bacteria 341 
were stained with iodide propidium (PI) in PBS 1X and again allowed to dry. Fluorescence images 342 
were taken with an Olympus IX70 inverted laser scanning confocal microscope, and captured using 343 
FluoView 200 software. 344 
 345 
2.8. Statistical analysis 346 
At least three independent experiments, each one in duplicate or triplicate, were performed for every 347 
investigational study. Numerical data are shown as means ± SEM for inferential results or as means ± 348 




as representative pictures. All data were analyzed by a one-way Analysis of Variance (ANOVA) 350 
followed by Tukey's post-hoc test (software: SPSS 16.0 for Windows, SPSS Inc., Chicago, IL). P<0.05 351 





3. Results  354 
 355 
3.1. Characterization of VmLNB and control (blank NB and Vm) formulations 356 
Before NB production, the interaction between dextran sulfate and Vm was firstly investigated to 357 
optimize Vm/dextran sulfate ratio. Results indicated that Vm was complexed at 99% by dextran sulfate 358 
solution until the concentration of 0.5 mg/mL (data not shown). The Vm/dextran sulfate ratio was 359 
calculated corresponding to 2:1 (w/w). Based on this preliminary information, NBs were prepared 360 
according to the protocol described in the Materials and Methods section. After manufacturing, 361 
VmLNB and blank NB formulations (with or without 6-coumarin in the inner core) were characterized 362 
physico-chemically. Results are shown in Figure 2 and Table 1. Both VmLNBs and NBs displayed 363 
spherical shapes with a core-shell structure by TEM analyses. All sizes were in the nanometer range, 364 
with all formulations displaying around 300 nm as a value for average diameters. All polidispersity 365 
indexes were included between 0.22 and 0.25. Zeta potentials ranged from -34 mV (NBs) to -29 mV 366 
(VmLNBs). The loading of Vm in the NB structure did not significantly affect the viscosity of the 367 
formulations. NBs were able to load Vm with an encapsulation efficiency of 86% and loading capacity 368 
of 29%.  369 
 370 
3.2. Stability of VmLNB and control (blank NB and Vm) formulations 371 
NB and VmLNB formulations proved to be physically stable over time, as confirmed by long-term 372 
checking of the parameters assessed in the previous paragraph. Indeed, the obtained values did not 373 
remarkably change up to six months after the manufacturing of the formulations stored at 4 °C (data 374 
not shown). Furthermore, the chemical stability of the drug was comparatively checked between free 375 
Vm solution and VmLNB aqueous suspension either over time (up to 14 days) or at different 376 




chemical point of view when properly incorporated in the nanocarrier (VmLNBs) than as such in 378 
solution. 379 
 380 
3.3. Human biocompatibility 381 
 382 
The potential toxicity of Vm solution and VmLNB suspension on human skin cells was assessed by 383 
testing in vitro cultured HaCaT keratinocytes. Cells were incubated for 24 h alone, with 10% v/v Vm 384 
solution, or with VmLNB nanosuspensions in normoxic conditions (20% O2). Thereafter, cytotoxicity 385 
was analyzed by LDH assay, and cell viability by MTT assay. As shown in Figure 4, neither Vm nor 386 
VmLNBs did show significant toxic effects and HaCaT cell viability was not significantly affected by 387 
either formulation.  388 
 389 
3.4. In vitro drug release from VmLNBs 390 
In vitro drug release from VmLNB nanosuspension and free Vm solution were comparatively 391 
evaluated over time. As shown in Figure 5 (time course studies up to 6 h) and Table 2 (end-point data 392 
up to 24 h), 1 mg/mL Vm release from VmLNBs was slow and prolonged over time, compared to free 393 
drug solution diffusion. No initial burst effect was observed indicating Vm incorporation in NB shell. 394 
Further information on additional incubation times and drug concentrations for VmLNBs is available in 395 
Supplementary Materials (Table S3). Vm/VmLNB drug release ratios at different times (2, 3, 4, 6, and 396 
24 h) were also calculated (see Table 2), in order to allow normalization of the results from treatment 397 







3.5. In vitro antimicrobial activity of VmLNBs 402 
According to preliminary microbiological analyses performed on the MRSA strain employed in the 403 
present experiments, 0.004 mg/mL resulted as the MIC value for Vm. Therefore, decreasing Vm 404 
concentrations from 1 mg/mL (used for the studies described in the previous paragraphs) to 0.004 405 
mg/mL (MIC value) were employed in a series of experiments aimed at comparatively evaluating Vm 406 
(either free or carried by VmLNBs) antibacterial effectiveness against MRSA. Bacteria were incubated 407 
at different times (2, 3, 4, 6, and 24 h) either alone (ctr) or with free Vm, VmLNBs, or blank NBs. The 408 
initial drug concentrations (1; 0.1; 0.01; and 0.004 mg/mL) loaded on VmLNBs were the same as those 409 
solved in free Vm solution. However, as emerged in the previous paragraph, drug release from 410 
VmLNBs is significantly slower than free Vm solution diffusion. For this reason, before proceeding 411 
with the analysis of the results, all values on bacterial growth referring to Vm- and VmLNB-treated 412 
samples were normalized upon time-dependent Vm/VmLNB drug release ratios shown in Table 2. 413 
Normalized results are shown in Figure 6, whereas raw data are available in Supplementary Materials 414 
(Figure S2). 1 mg/mL Vm effectively inhibited bacterial growth at all times, independently from being 415 
free or carried by the nanocarrier. Lower drug concentrations of free Vm solution were effective 416 
against MRSA only after longer times of incubation (at least 3 h for 0.1 mg/mL and 0.01 mg/mL Vm; 417 
and at least 4 h for 0.004 mg/mL Vm). Interestingly, Vm antibacterial efficacy was significantly 418 
improved when the drug was carried by VmLNBs. Indeed, VmLNB-dependent inhibition of bacterial 419 
growth was significantly enhanced compared to free Vm solution, at all drug concentrations. 420 
Additionally, compared to free Vm solution, VmLNB antibacterial effects appeared earlier, as they 421 
were already evident after 2 h of incubation (the first time-point of the observational period) at all Vm 422 




Further analysis by confocal microscopy (Figure 7) displayed that MRSA avidly internalized free 424 
fluorescent Vm already after 2 h of incubation, but not fluorescent VmLNBs. Fluorescent Vm-free NBs 425 
did adhere to the bacterial cell wall without being internalized.  426 
3.6. US-triggered drug permeation 427 
The ability of US to promote Vm permeation through the skin was assayed by employing a purposely 428 
modified Franz cell constituted by a donor and a recipient chamber separated by a pig skin layer (see 429 
Figure 8A for a schematic representation of the apparatus). As shown in Figure 8B, the administration 430 
of US (t = 10 min; f = 2.5 MHz; P = 5 W) strongly induced VmLNBs to deliver the antibiotic drug 431 
from the donor chamber throughout the pig skin membrane into the recipient chamber up to 6 h. 432 
Furthermore, drug accumulated in the skin after US treatment reached 158 g/cm
2 








4. Discussion 438 
 439 
Vm currently represents the main stay against MRSA infections (Koyama et al., 2013; Kullar et al., 440 
2016). However, Vm administration raises several issues that urgently need to be faced, including its 441 
marked instability, low oral bioavailability, complex concentration-time profile, low tissue penetration 442 
(ranging from 10% in diabetic to 30% in normal skin and soft tissues), and several adverse effects 443 
(Mawhinney et al., 1992; Raverdy et al., 2013; Vandecasteele et al., 2012; Vidal et al., 1992; Giandalia 444 
et al., 2001). In the attempt to counteract these drawbacks, thus improving the effectiveness of Vm 445 
delivery, some novel nanocarriers have been developed: i) Vm coupling to chitosan as an ocular drug 446 
delivery vehicle for topical use in rabbit eyes has appeared more effective than carrier-free Vm 447 
(Khangtragool et al., 2011); ii) PEGylated liposomal Vm enhanced the effective treatment of MRSA 448 
pneumonia and simultaneously reduced the nephrotoxicity risk compared with conventional and non-449 
PEGylated Vm formulations (Muppidi et al., 2011); iii) Vm-loaded liposomes, stabilized with chitosan 450 
modified gold nanoparticles bounded to their surface, have proven effective in inhibiting the bacterial 451 
growth (Pornpattananangkul et al., 2011); and iv) Vm-containing trehalose and hydroxyethylcellulose 452 
spherical matrices have been developed as new delivery systems suitable for topical applications on 453 
extensive and purulent wounds (Giandalia et al., 2001). Recently, Vm-loaded polymersosomes were 454 
developed from a novel pegylated oleic acid polymer for sustained antibiotic delivery (Omolo et al., 455 
2017). Overall, these works represent the proof-of-principle for the feasibility of choice of nanocarriers, 456 
as alternative drug delivery systems to obtain the desired drug release rates and bioavailability 457 
(Kalhapure et al., 2015). However, the effectiveness of those nanocarriers was seriously undermined by 458 
their poor ability to cross the stratum corneum, a skin barrier displaying low permeability unless proper 459 




For these reasons, the present study aimed at developing Vm nanocarriers as a new platform to be 461 
effectively and safely employed for Vm topical administration to treat wound infections. To this 462 
purpose, NBs with core-shell nanostructures were identified as first choice carriers due to their known 463 
benefits in association with drug delivery, including small size, stability, suitability for drug loading, 464 
responsiveness to external stimuli such as US, and controlled drug release abilities (Marano et al., 465 
2016; Cavalli et al., 2009a; Cavalli et al., 2009b; Cavalli et al., 2016). In this study, dextran sulfate was 466 
chosen as main constituent of the polysaccharidic shell as a consequence of the large amount of data 467 
from the literature supporting dextran biocompatibility (Bos et al., 2005; De Groot et al., 2001). 468 
Encouragingly, dextran-based hydrogels have already been employed as matrices in tissue engineering, 469 
without showing signs of inflammation in vivo (Möller et al., 2007), and recent toxicological studies 470 
have shown that dextran, as well as the products from its mechano-chemical processing, can be 471 
classified as class 4 (low-toxicity) substances (Dushkin et al., 2013). Moreover, dextran sulfate presents 472 
a negative charge that can electrostatically interact with the positive charged Vm. On the other hand, 473 
PFP was employed as principal constituent of the inner core, since it is the most widely used 474 
fluorocarbon in oxygenating emulsions and NB formulations (Cabrales and Intaglietta, 2013, Castro 475 
and Briceno, 2010). In order to load Vm, dextran sulfate-shelled/PFP-cored NBs were then 476 
functionalized by exploiting the electrostatic interactions occurring between the negatively charged 477 
sulfate groups of the shell and the protonated amino groups of the drug. The obtained VmLNBs 478 
displayed a spherical shape and a well-defined core-shell structure with a polymeric shell thickness of 479 
about 40 nm, average diameters of 300 nm,  viscosity of 1.25 cP, and negatively charged surfaces. Of 480 
note, the observed decrease of zeta potential values of ~ 15 % for VmLNBs (around -29 mV) with 481 
respect to blank NBs (around -34 mV) confirmed the occurrence of electrostatic interactions between 482 




charge neutralization of the bubble surface and allowing a good Vm encapsulation efficiency (86%) 484 
and loading capacity (29%) in the NB systems.  485 
In addition, it should be noticed that since the zeta potential measures charge repulsion or attraction 486 
between particles, it represents a fundamental parameter to avoid nanoparticle aggregation, with zeta 487 
potentials lower than -25 mV or larger than +25 mV being generally required for physical stability of 488 
colloid systems (Shah and Eldridge, 2014). The stability of VmLNB formulations was further 489 
confirmed by long-term checking of their size, surface charge, and viscosity values, which did not 490 
show any significant changes up to six months after manufacturing, stored at 4 °C. On the other hand, 491 
drug stability was comparatively checked between free Vm solution and VmLNB suspension either 492 
over time (up to 14 days) or at different temperatures (25°C and 37°C), revealing an increased stability 493 
for Vm when properly encapsulated in the nanocarriers. This appears as an undoubtedly advantageous 494 
feature for VmLNB formulations, since they might prove useful to overcome the reported instability of 495 
Vm in aqueous solutions at body temperature (Mawhinney et al., 1992, Raverdy et al., 2013). 496 
Interestingly, VmLNBs displayed a slow and prolonged drug release kinetics compared to Vm aqueous 497 
solution, with only 16% of the drug being released from VmLNBs after 6 h. These data support the 498 
hypothesis that VmLNBs may be employed as an effective drug reservoir until reaching the target site, 499 
where the antibiotic would be released upon sonication at an appropriate moment only. The features of 500 
VmLNBs might be exploited for the design of innovative wound dressing following their inclusion in 501 
polymeric base. Indeed, NBs can be dispersed in polymer gel without changing physico-chemical 502 
characteristics, as previously showed (Prato et al., 2015). Another intriguing feature of VmLNBs relies 503 
on the reported evidence that surface charges play a pivotal role in making a nanoparticle suitable for 504 
topical treatment, since they enhance its interaction with the skin and improve its therapeutic effect on 505 
inflamed cutaneous tissues, either without (Abdel-Mottaleb et al., 2012) or with concomitant US 506 




treatment due to the anionic nature of the skin (Wu et al., 2010), some authors have shown that anionic 508 
nanoparticles can be more effective (Lee et al., 2013) and less toxic (Ryman-Rasmussen et al., 2007) 509 
than the cationic ones. These latter data appear  consistent with our results through investigation by 510 
biochemical assays to assess VmLNB biocompatibility with human skin tissues. Indeed, VmLNBs did 511 
not induce any in vitro cytotoxic effects on HaCaT keratinocytes, a skin cell line that was originally 512 
immortalized from a 62-year old donor (Boukamp et al., 1988). This peculiar information strengthens 513 
remarkably the evidence on VmLNB safety for future topical applications. 514 
VmLNB and carrier-free Vm antimicrobial activity against MRSA were comparatively investigated, 515 
also analyzing Vm and NB physical interaction with the bacterial cell wall by confocal microscopy.  516 
Interestingly, VmLNBs were more effective in MRSA bacterial growth inhibition then free Vm, 517 
promoting enhanced and earlier antibacterial effects, although they were not internalized by bacteria, 518 
opposite to free Vm. This behavior appears to be a likely consequence of time-sustained release of Vm 519 
from VmLNBs. 520 
Notably, an important issue that requires caution while evaluating the feasibility for any topical drug 521 
treatment is represented by the considerably low degree of permeability of the skin, the primary 522 
defense system for the body. This organ consists of several layers, including the stratum corneum, the 523 
epidermis, and the dermis. In particular the stratum corneum - composed of corneocytes interspersed in 524 
a laminate of compressed keratin and intercorneocyte lipid lamellae - is very poorly permeable to 525 
foreign molecules and represents the main obstacle to transdermal drug delivery (Naik et al., 2000). 526 
However, an ideal antibiotic drug formulation should be efficiently localized in the epidermis/dermis 527 
and provide a sustained drug release over time (Prabhu et al., 2012). To allow a drug to penetrate the 528 
skin, several approaches have been proposed, including skin patches, ionophoresis, chemical 529 




Interestingly, antimicrobial properties have been reported for US, although its effectiveness strongly 531 
varies depending on the targeted type of pathogen (fungi vs bacteria; cocci vs bacilli; Gram-positive vs 532 
Gram-negative) (Sango et al., 2014). Furthermore, synergistic effects between US and antibiotics have 533 
been reported in a series of studies: i) antibiotic treatment coupled with US irradiation resulted in 534 
enhanced bactericidal activity against both Gram-positive and Gram-negative bacteria, especially for 535 
aminoglycosides (Yu et al., 2012); ii) the combination of Vm and US decreased S. aureus viable counts 536 
by two orders of magnitude compared to Vm alone (Ayan et al., 2008); and iii) the addition of NB-537 
enhanced US to doxycycline treatment improved the drug effectiveness in eradicating intracellular 538 
Chlamydia trachomatis (Ikeka-Dantsuji et al., 2011). US-dependent enhancement of antibiotic action 539 
      f     w       d      ‘      u      ff   ’  I         g    V       f    h  ugh S. epidermidis 540 
biofilms was shown to be significantly enhanced by US, with bubbles being able to increase the biofilm 541 
permeability to Vm (Dong et al., 2013).  542 
As discussed previously, VmLNBs can be effectively employed as an important reservoir to store the 543 
drug until trespassing the stratum corneum of the skin  and reaching the target site. In order to achieve 544 
the latter goal, US was assayed for its ability to induce VmLNBs to trespass an in vitro cutaneous layer, 545 
thereby releasing Vm throughout the skin. Notably, the skin from the pig ear is widely recognized as a 546 
good model for human skin permeability, since it displays human-like histological and physiological 547 
properties, including epidermal thickness and composition, dermal structure, lipid content and general 548 
morphology (Dick and Scott, 1992). The validity of the porcine model has been established by 549 
comparing the permeability of simple marker molecules with the corresponding values across human 550 
skin (Herkenne et al., 2006, Sekkat et al., 2002). Therefore, the porcine ear skin represents so far the 551 
most accountable in vitro model to mimic the human skin in studies on percutaneous penetration 552 
(Jacobi et al., 2007). In our experiments, US appeared essential to promote Vm release from VmLNBs 553 




the passive transport of free vancomycin hydrochloride was negligible, being a charged and hydrophilic 555 
molecule. The amount of Vm accumulated in the skin after US application combined with NBs was 556 
greater than MIC value. 557 
 558 
5. Conclusions 559 
In the present work, dextran sulfate-shelled and PFP-filled NBs were developed for Vm delivery. 560 
VLNBs proved to be effective in MRSA bacterial killing without showing toxic effects on human 561 
keratinocytes. The combination of NBs and US enhanced Vm permeation through pig skin and 562 
promoted drug skin accumulation. Based on these results, Vm topical administration through proper 563 
NB formulations might be a promising strategy for the local treatment of MRSA skin infections.  The 564 
study represents the proof of concept for the future development of advanced multifunctional 565 
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Figure legends 830 
 831 
Figure 1. Schematic structure of VmLNB formulations. Vm nanocarriers described in the present 832 
work display a core-shell structure. PFP was employed as core fluorocarbon, whereas dextran sulfate 833 
was chosen as polysaccharidic shell molecule. Vm was inserted into the outer shell throughout dextran 834 
sulfate chains. In selected experiments, VmLNBs were further functionalized by including fluorescent 835 
6-coumarin in the inner core. 836 
 837 
Figure 2. NB and VmLNB morphology. NBs and VmLNBs were checked for morphology by TEM. 838 
Results are shown as representative images from three different preparations. Panel A. NB image by 839 
TEM. Panel B. VmLNB image by TEM. (see also Figure S1 in Supplementary Materials for additional 840 
images of multiple nanobubbles within the same field). 841 
 842 
Figure 3. Stability of Vm and VmLNB formulations. The stability of Vm solution and VmLNB 843 
suspension was monitored up to 14 days either at room temperature (Panel A) or at 37°C (Panel B) 844 
through analysis by HPLC. Results are shown as means ± SD from three different preparations for each 845 
formulation. Data were also analyzed for significance by ANOVA. Versus Vm solution: * p<0.001. 846 
 847 
Figure 4. Biocompatibility of Vm and VmLNBs with  human keratinocytes in vitro. HaCaT cells 848 
(10
6
 cells/2 mL DMEM medium implemented with 10% FCS) were left untreated (ctr) or treated with 849 
200 L of Vm solution or VmLNB suspension for 24 h in normoxia (20% O2). Thereafter, Vm and 850 
VmLNB cytotoxicity were measured through LDH assay (Panel A), whereas cell viability was 851 




experiments. Data were also evaluated for significance by ANOVA. No significant differences were 853 
found among all conditions. 854 
Figure 5. In vitro Vm release from Vm and VmLNB formulations. Vm release from Vm solution 855 
and VmLNB suspension was monitored up to 6 h. Results are shown as means ± SD from three 856 
different preparations for each formulation. Data were also analyzed for significance by ANOVA. 857 
Versus Vm solution: * p<0.001.  858 
 859 
Figure 6. Antibacterial activity of Vm and VmLNBs against MRSA. MRSA were left for 2, 3, 4, 6 860 
and 24 hours at 37°C alone (ctr) or incubated with 10% v/v NBs or different concentrations of Vm, 861 
either free or loaded on VmLNBs (Panel A: 1 mg/mL; Panel B: 0.1 mg/mL; Panel C: 0.01 mg/mL; 862 
Panel D: 0.004 mg/mL). Results are shown as means ± SEM from three independent experiments. Data 863 
on Vm- and VmLNB-treated samples were normalized upon Vm/VmLNB release ratios reported in 864 
Table 2 (see also in Supplementary Materials: Table S3 for further information on percentages of drug 865 
release from VmLNBs at different times/concentrations; and Figure S2 for raw data on VmLNB 866 
antibacterial effects). All data were also evaluated for significance by ANOVA. Versus ctr: * p < 0.02; 867 
versus Vm: ° p < 0.05.  868 
 869 
Figure 7. Drug loading on dextran sulfate-shelled NBs prevents Vm internalization by MRSA. 870 
MRSA were left alone or incubated with 10% v/v 6-coumarin-labeled VLNBs, 6-coumarin-labeled 871 
NBs, and FITC-labeled Vm for 2h at 37°C. After staining bacteria with PI, confocal fluorescent images 872 
were taken using FITC and TRITC filters. Data are shown as representative images from three 873 





Figure 8. US-triggered sonophoresis of VmLNBs through skin membranes. US (t = 10 min; f = 2.5 876 
MHz; P = 5 W) abilities to induce sonophoresis and Vm permeation from VmLNBs were evaluated up 877 
to 6 h by using a vertical diffusion Franz cell consisting in two chambers (donor and recipient, 878 
respectively) separated by a pig skin layer (see scheme in Panel A). Results are shown in Panel B as 879 
means ± SD from three independent experiments. Data were also evaluated for significance by 880 




Tables and legends 882 
 883 
Formulation Average diameter 
± SD (nm) 
Polydispersity  
index 
Zeta Potential  
± SD (mV) 
Viscosity 
(cP) 
NBs 313.4 ±  26.4 0.24 ± 0.02 - 34.5 ± 0.38 1.22 
VmLNBs 304.6 ± 14.6 0.22 ± 0.03 - 28.6 ± 1.34 1.25 
Fluorescent NBs 312.8 ±  22.7 0.25 ± 0.02 - 34.1 ± 1.22 1.24 
Fluorescent VmLNBs 308.9 ± 22.4 0.23 ± 0.01 - 29.5 ± 1.88 1.23 
 884 
Table 1. Physical-chemical characterization of NBs and VmLNBs. Liquid formulations were 885 
characterized for average diameters, polydispersity index, and zeta potential by light scattering. The 886 
viscosity (cP) of NB and VmLNB suspensions was determined at 25 °C by using a Ubbelohde capillary 887 
viscosimeter. Results are shown as means ± SD from three preparations. See also Figures 1-2 for 888 














% drug release from 
Vm solution 
% drug release  
from VmLNBs 
Vm/VmLNB 
drug release ratio 
2 36.57 5.99 6.11 
3 45.97 7.97 5.78 
4 57.16 10.27 5.57 
6 73.44 14.59 5.03 
24 92.34 35.84 2.58 
 898 
Table 2. In vitro drug release from Vm solution and VmLNB suspension. After incubation for 899 
increasing times (first column), the percentages of in vitro drug release from Vm solution (second 900 
column) and VmLNB suspension (third column) were measured. Then, Vm/VmLNB drug release 901 
ratios (fourth column) were calculated for each time considered.  All incubation times (2, 3, 4, 6, and 902 
24 h) were purposely chosen to further normalize the results from the experiments with MRSA (see 903 
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Vancomycin (Vm) currently represents the gold standard against methicillin-resistant Staphylococcus 25 
aureus (MRSA) infections. However, it is associated with low oral bioavailability, formulation stability 26 
issues, and severe side effects upon systemic administration. These drawbacks could be overcome by 27 
Vm topical administration if properly encapsulated in a nanocarrier. Intriguingly, nanobubbles (NBs) 28 
are responsive to physical external stimuli such as ultrasound (US), promoting drug delivery. In this 29 
work, perfluoropentane (PFP)-cored NBs were loaded with Vm by coupling to the outer dextran sulfate 30 
shell. Vm-loaded NBs (VmLNBs) displayed ~300 nm sizes, anionic surfaces and good drug 31 
encapsulation efficiency. In vitro, VmLNBs showed prolonged drug release kinetics, not accompanied 32 
by cytotoxicity on human keratinocytes. Interestingly, VmLNBs were generally more effective than 33 
Vm alone in MRSA killing, with VmLNB antibacterial activity being more sustained over time as a 34 
result of prolonged drug release profile. Besides, VmLNBs were not internalized by staphylococci, 35 
opposite to Vm solution. Further US association promoted drug delivery from VmLNBs through an in 36 
vitro model of porcine skin. Taken together, these results support the hypothesis that proper Vm 37 
encapsulation in US-responsive NBs might be a promising strategy for the topical treatment of MRSA 38 
wound infections. 39 
 40 
Key words 41 





1. Introduction 44 
 45 
Chronic wounds fail to proceed through timely regulated and interrelated processes to restore 46 
anatomical and functional integrity of the injured tissues (Lazarus et al., 1994) such as diabetic feet, 47 
bedsores, and venous ulcers (Markova et al., 2012). To date, these types of wounds are considered like 48 
a silent epidemic, affecting a large fraction of the world population and posing a major gathering threat 49 
to the public health and economy of all developed countries (Daeschlein, 2013). Hospitalized patients 50 
are at particular risk, especially those suffering from diabetes, human immunodeficiency virus or other 51 
immune disorders, as well as those undergoing chemotherapy (Payne et al., 2008).  52 
Beyond delayed healing processes due to different factors (hypoxia, persistent inflammation, and 53 
altered balances between tissue remodelling proteinases and their inhibitors), chronic wounds are often 54 
worsened by microbial infections (Gurusamy et al., 2013). Among the bacteria responsible for skin 55 
infection, Staphylococcus aureus represents the most common pathogen to be identified in chronic 56 
wounds, with methicillin-resistant S. aureus (MRSA) accounting for upward of 20% to 50% of cases 57 
(Price, 2010). MRSA colonies often develop at the interface between synthetic prostheses and 58 
biological tissues, particularly during surgery and post-surgery course. In addition, MRSA colonization 59 
or infection of wounds can result in MRSA bacteremia, which is associated with a 30-day mortality of 60 
about 28% to 38% patients (Gurusamy et al., 2013).  61 
The main goal of chronic wound treatment is to decrease the injuring-associated microbial load, thus 62 
allowing wound healing processes to take place. However, conventional systemic delivery of 63 
antibiotics not only entails poor penetration into ischemic and necrotic tissues, but can also cause 64 
systemic toxicity with associated renal and liver complications, resulting in forced hospitalization for 65 




proven effective in decreasing bacterial levels in granulating wounds (Diehr et al., 20087). Therefore, 67 
alternative local delivery of antimicrobials - either by topical administration or through novel delivery 68 
devices - may enable to keep high local antibiotic concentrations for prolonged release times without 69 
reaching systemic toxicity (                   2008).  70 
A promising approach to develop a topical therapy for microbial infection in skin and soft tissues 71 
would employ biocompatible nanomaterials and drug nanocarriers. Indeed, nanotechnology represents 72 
an emerging field to be exploited for antibiotic drug delivery. Thanks to their physical and chemical 73 
properties (small size, high surface-to-volume ratio and suitable surface modification) nano-sized 74 
materials may be used as drug carriers to trespass several physiological barriers and to reach biological 75 
targets. The coupling of nanocarriers with anti-infectious agents makes it likely to increase drug 76 
concentrations and drug penetration at the site of infection. As a result, it might not only improve the 77 
therapeutic index but also reduce some issues associated with nonspecific cytotoxicity and antibiotic 78 
resistance (Sharma et al., 2012).  79 
Vancomycin hydrochloride, being effective against many Gram-positive bacteria that are unresponsive 80 
to common antibiotics, represents the gold standard against MRSA infections (Kullarrrant et al., 2016). 81 
However, Vm is poorly absorbed from the gastrointestinal tract with a low oral bioavailabiliy. Low 82 
intravenous infusion is often suggested as a feasible alternative for drug administration, but Vm 83 
instability in aqueous solutions at 37°C could imply a tremendous reduction of drug effectiveness 84 
(Mawhinney et al., 1992; Raverdy et al., 2013). Following parenteral administration, Vm displays a 85 
slow mode of action, a complex concentration-time profile, and a disappointingly low penetration in 86 
tissues  (Vandecasteele et al., 2012). Furthermore, systemic Vm administration can be associated with 87 
several adverse effects (Vidal et al., 1992). On the other hand, Vm topical application – that would be 88 
much safer than systemic administration - is currently limited by several factors such as skin barrier 89 




treatment to decrease the microbial load, allowing the healing processes to take place, new delivery 91 
protocol should be devised, since conventional systemic delivery of antibiotics requires a drug 92 
concentration which is locally ineffective because of the poor penetration into ischemic and necrotic 93 
tissues, but can cause systemic toxicity and topically applied antimicrobials have proven effective in 94 
decreasing bacterial levels in granulating wounds (Diehr et al., 2007), without inducing          95 
                             2008) but suffer from poor diffusion across membranes. 96 
Intriguingly, the use of a nanocarrier may help to avoid the abovementioned drawbacks. Notably, 97 
nanocarriers such as liposomes, microemulsions, and lipid nanoparticles have the potential to deliver 98 
drugs to the skin more efficiently than conventional topical carriers such as creams and ointments, that 99 
are not usually recommended for applications on injured skin (Giandalia et al., 2001; Prabhu et al., 100 
2012). However, the response to drug topical applications has been too weak so far, mainly due to the 101 
inability to cross the external skin barrier (stratum corneum) and reach the dermal regions where the 102 
bacteria are nested. Interestingly, physical media such as ultrasound (US) are reportedly able to trigger 103 
drug release at the site of infection by temporarily increasing skin permeability through sonophoresis. 104 
As such, US is useful to promote drug targeting and transdermal delivery in a non-invasive manner 105 
(Azagury et al., 2014; Park et al, 2012).  106 
Microbubbles (MBs) (Guiot et al., 2006), nanobubbles (NBs) (Cavalli et al., 2009a; Cavalli et al., 107 
2009b; Cavalli et al., 2016) and nanodroplets (NDs) (Magnetto et al., 2014; Prato et al., 2015) are 108 
suitable carriers to be combined with such a physical trigger. They are spherical core-shell structures 109 
filled with gases such as perfluorocarbons. Particularly, oxygen-cored nanostructures  can be employed 110 
both for sonography (as contrast agents) (Fokong et al., 2012; Marxer et al., 2011) and for therapy (as 111 
hypoxia- and infection-counteracting devices) (Gulino et al., 2015; Banche et al., 2015; Khadjavi et al., 112 
2015; Basilico et al., 2015; Prato et al., 2016). In particular NBs, consisting in an outer shell of a 113 




filled with an oxygen-storing fluorocarbon (perfluoropentane, PFP), have been purposely developed as 115 
a new non-invasive, low-cost and multipurpose nanotechnological platform (Cavalli et al., 2009a; 116 
Cavalli et al., 2009b; Cavalli et al., 2016). PFP is a perfluorocarbon with a boiling point of 29°C, hence 117 
liquid at room temperature. The use of PFP allows liquid droplet generation at room temperature. Then, 118 
PFP in nanodroplets can be activated by an external stimulus, like US, by means of a mechanism called 119 
acoustic droplet vaporization, causing the droplet to become a bubble. Depending on the properties of 120 
the nanostructure, NBs can be subsequently coupled with different molecules, such as drugs or genetic 121 
materials, thus acting as nanocarriers (Cavalli et al., 2012; Cavalli et al., 2013; Delalande et al., 2012; 122 
Yin et al., 2014). Due to their structure and their gaseous core, NBs are very responsive to US and can 123 
take advantage from a number of effects related to microcavitation and microstreaming, occurring at 124 
the liquid-membrane interface and responsible for transitory and reversible openings of the pores, thus 125 
crossing the membrane itself and delivering their content beyond the tissue (sonophoresis) or the cell 126 
(sonoporation) membrane (Karshafian et al., 2009).  127 
Based on these preconditions, the present work aimed at producing dextran sulfate-shelled and PFP-128 
cored NBs for Vm local delivery to potentially treat skin infectious diseases. The formulation is 129 
  f    d       “     u     ” f     k   f    p        u      u   be said that, prior to the application of 130 
US, it would be more accurate    u    h       “    d  p    ” wh    h                 u  d  f PFP. 131 
Therefore, Vm-loaded NBs (VmLNBs) were prepared and characterized for physico-chemical 132 
parameters and drug release kinetics; tested for biocompatibility with human skin cells and for their 133 
antibacterial properties or interactions with MRSA; and challenged for responsiveness to US, in order 134 





2. Material and methods 137 
 138 
2.1. Materials  139 
All materials were from Sigma-Aldrich, St Louis, MO, unless those indicated as follows. Sterile 140 
plastics were from Costar, Cambridge, UK; ethanol (96%) was from Carlo Erba (Milan, Italy); soybean 141 
lecithin (Epikuron 200
®
) was from Cargill (Hamburg, Germany); 1-800 Millipore system to obtain 142 
ultrapure water and Amicon
®
 Ultra-0.5 centrifugal filter device were from Millipore (Molsheim, 143 
France); Ultra-Turrax SG215 homogenizer was from IKA (Staufen, Germany); RPMI 1640 medium 144 
was from Invitrogen (Carlsbad, CA); Nanobrook 90Plus Particle Size Analyzer was from Brookhaven 145 
(New York City, NY); Philips CM10 electron microscope was from Philips (Eindhoven, the 146 
Netherlands); Ubbelhode capillary viscosimeter was from SCHOTT Instruments GmbH (Mainz, 147 
Germany); Perkin Elmer PUMP 250B was from Perkin Elmer (Waltham, MA); Flexar UV/Vis LC 148 
spectrophotometer detector was from Perkin Elmer (Waltham, MA); Agilent TC C18 columns were 149 
from Agilent (Santa Clara, CA); Orion Model 420A pH Meter was from Thermo Scientific (Waltham, 150 
MA); Semi-Micro Osmometer K-7400 was from Knauer (Berlin, Germany); Beckman Coulter Allegra 151 
64R Centrifuge was from Beckman Coulter (Brea, CA); Spectra/Por cellulose membranes were from 152 
Spectrum Laboratories  (Rancho Dominguez, CA); HaCaT cells were from Cell Line Service GmbH 153 
 Epp  h     G      );       u  u   RPMI 1640   d Du      ’    d f  d E g  ’    d u   DMEM) 154 
were from Invitrogen (Carlsbad, CA); streptomycin was from Cambrex Bio Science (Vervies, 155 
Belgium); humidified CO2/air-incubator was from Thermo Fisher Scientific Inc. (Waltham, MA); 156 
tryptic soy broth (TSB) and tryptic soy agar (TSA) were from Merk KgaA (Darmstadt, Germany); 157 
Olympus Fluoview 200 laser scanning confocal system mounted on an inverted IX70 Olympus 158 
microscope was from Olympus America Inc. (Melville, NY, USA) ; SPSS 16.0 software was from 159 





2.2. Development and manufacturing of formulations  162 
 163 
2.2.1. Determination of Vm and dextran sulfate interaction ratio 164 
Increasing concentrations (0.25, 0.5, 1.0, 2.0 mg/mL) of dextran sulfate aqueous solutions (1 mL) were 165 
added to 1 mL of Vm aqueous solution (1 mg/mL) under magnetic stirring at room temperature 166 
overnight. After equilibration, the systems were separated by centrifugation (20000 rpm, 15 minutes) 167 
using a centrifugal filter device (Amicon
®
 Ultra), in order to determine the amount of unbound Vm in 168 
the filtrate phase. The drug concentration in the filtrate was determined using the HPLC method 169 
described below. 170 
 171 
2.2.2. Preparation of NB, Vm, and VmLNB formulations 172 
NBs were formulated using PFP for the inner core and dextran sulfate for the shell. A purposely tuned 173 
multi-step protocol was designed. Briefly, a pre-emulsion was obtained adding 300 mL of an ethanol 174 
solution containing Epikuron
®
 200 and palmitic acid (1% w/v) to 500 L of PFP under magnetic 175 
stirring. After the addition of 4.8 mL of ultrapure water, the system was homogenized using a Ultra-176 
Turrax SG215 homogenizer. To obtain the polymeric NBs, 350 L of 1% w/v dextran sulfate 177 
(molecular weight = 100 kDa) aqueous solution was added drop-wise under magnetic stirring. Blank 178 
NBs obtained according to this procedure were employed as control formulations in the subsequent 179 
experiments. On the other hand, to obtain VmLNBs, an extra step based on drop-wise addition of a Vm 180 
aqueous solution (pH 3.5) to the so-formed NBs was performed under mild stirring. Different 181 
concentrations of Vm solutions were added to prepare a series of VmLNB formulations with increasing 182 




unbound molecules. For selected experiments, fluorescent NBs and VmLNBs were obtained by the 184 
addition of 6-coumarin (1 mg/mL) to the PFP core. Alternatively, fluorescent Vm was synthesized 185 
through reaction between fluorescein isothiocyanate (FITC) and Vm. For this purpose, an amount of 186 
FITC solution in methanol (0.2 % w/v) was added to Vm aqueous solution and incubated under stirring 187 
overnight in the dark. Figure 1 shows a representative scheme resuming the general structure of 188 
fluorescent VmLNBs. For cell experiments, NBs were prepared in phosphate buffer saline pH 7.4 189 
(PBS). For in vitro permeation studies, NBs were prepared in saline solution (NaCl 0.9% w/v). 190 
 191 
2.2.3. NB sterilization 192 
Firstly, the glassware and the components were sterilized at 121 °C and 2 bar. Subsequently, all NB 193 
formulations were sterilized through UV-C exposure for 20 min. Thereafter, UV-C-treated materials 194 
were incubated with cell culture RPMI 1640 medium in a humidified CO2/air-incubator at 37°C up to 195 
72 h, not displaying any signs of microbial contamination when checked by optical microscopy.  196 
 197 
2.3. Characterization of formulations 198 
 199 
2.3.1. Characterization of NB and VmLNB formulations 200 
The average diameter, polydispersity index and zeta potential were determined by photocorrelation 201 
spectroscopy using a particle size analyzer at a scattering angle of 90° and a temperature of 25 °C. NB 202 
suspensions were diluted in deionized filtered water before measurement. For zeta potential 203 
determination, samples of diluted NB formulations were placed in the electrophoretic cell, where an 204 
electric field of approximately 15 V/cm was applied. The morphology of formulations was evaluated 205 
by Transmission Electron Microscopy (TEM), using a Philips CM10 (Eindhoven, NL) instrument. NB 206 





observation. The viscosity of the samples was determined at 25 °C using a Ubbelhode capillary 208 
viscosimeter. 209 
 210 
2.3.2. HPLC quantitative Vm determination  211 
Vm quantitative determination was carried out by using an HPLC system based on a Perkin Elmer 212 
pump equipped with a spectrophotometer detector. Analyses were performed using an Agilent TC C18 213 
column (250 mm × 4.6 mm, 5 µm). The mobile phase was a mixture of KH2PO4 50 mM (pH 4) and 214 
acetonitrile (92:8 v/v), degassed and pumped through the column with a flow rate of 1 mL/min. 215 
Ultraviolet detection was set at 286 nm. The external standard method was used to calculate the drug 216 
concentration. For this purpose, 1 mg of Vm was weighted, placed in a volumetric flask, and dissolved 217 
in water to obtain a stock standard solution. This solution was then diluted using the mobile phase, 218 
providing a series of calibration solutions, subsequently injected into the HPLC system. Linear 219 
calibration curve was obtained over the concentration range of 0.5−25 μg/mL, with a regression 220 
coefficient of 0.999. 221 
 222 
2.3.3. In vitro evaluation of Vm stability 223 
Vm chemical stability - either solved in aqueous solution or loaded in VmLNBs - was evaluated at 224 
room temperature and at 37 °C over time. A quantitative determination of Vm concentration over time 225 
was carried out using the HPLC method described above.  226 
 227 
2.3.4. NB stability over time and after US administration 228 
The physical stability of NBs was evaluated by morphological analysis and by size and zeta potential 229 
determination of formulation over time. Their average diameters, zeta potential values and morphology 230 




0.1 MHz; t = 10 min; P = 5 W). NB morphology was observed by TEM to confirm the integrity of NB 232 
structure. 233 
  234 
2.3.5. Encapsulation efficiency and loading capacity of Vm in NBs 235 
The encapsulation efficiency of VmLNBs was determined using a centrifugal filter system. 150 236 
microL of VmLNB suspension were put in an Amicon
®
 Ultra-0.5 centrifugal filter device and 237 
centrifuged at 15000 rpm for 30 minutes using Beckman Coulter Allegra 64R Centrifuge. The solution 238 
filtered in the bottom of the tube was quantified and after suitable dilution was analyzed by HPLC, in 239 
order to obtain the concentration of free Vm in VmLNBs suspensions. The encapsulation efficiency 240 
was calculated by subtracting the amount of free drug from the initial amount of added Vm, according 241 
to the following equation:  242 
 243 
The loading capacity was determined on freeze-dried NB samples. Briefly, a weighted amount of 244 
freeze-dried VmLNBs was suspendeddiluted in 105 mL of water. After sonication and centrifugation, 245 
the supernatant was diluted with mobile phase and analyzed by HPLC. The loading capacity of Vm in 246 
VmLNBs was calculated as follows: 247 
 248 
 249 
2.4. In vitro release studies 250 
In vitro drug release experiments were conducted in a multi-compartment rotating cell, comprising a 251 
donor chamber separated by a cellulose membrane (cut-off = 12000 Da) from a receiving compartment. 252 




in the donor chamber. The in vitro release kinetics of Vm from VmLNB was compared to a Vm 254 
aqueous solution (1 mg/mL) as a control. The receiving phase, containing phosphate buffer 0.05 M (pH 255 
7.4) was withdrawn at regular intervals and replaced with the same amount of fresh buffer. Quantitative 256 
determination of Vm in the withdrawn samples was carried out by the HPLC method, as described in 257 
the previous paragraph. Data were expressed as % of Vm released over time.  258 
 259 
2.5. In vitro permeation study  260 
In vitro studies were performed using a vertical diffusion Franz cell to evaluate Vm permeation 261 
throughout the skin. The Franz cell consists of a donor compartment, with Vm (1 mg/mL, either free or 262 
carried by VmLNBs, 1x10
12
 NBs/ml) and a receiving compartment containing 0.9% w/w NaCl saline 263 
solution. To simulate the stratum corneum properties a membrane pig ear skin was used. Skin slices 264 
were isolated with a dermatome from the outer side of pig ears, obtained from a local slaughterhouse, 265 
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% w/w saline solution, in the presence of 0.01% sodium azide to preserve the skin, at 25 °C for 30 min. 267 
Then, after washing with saline solution, the skin layer was inserted between the two compartments of 268 
the Franz cell, with the stratum corneum side facing towards the donor chamber. The study was carried 269 
out for 24 hours and the receiving phase was withdrawn at regular times and replaced with the same 270 
amount of fresh receiving medium. The collected samples were then analyzed by HPLC to determine 271 
the amount of Vm permeated over time. US abilities to promote Vm permeation were also investigated. 272 
For this purpose, a high frequency US transducer (f = 2.5 MHz; P = 5 W; t = 10 min) was combined to 273 
a purposely modified vertical diffusion cell. Drug permeation through pig skin after US application was 274 








2.6. Human biocompatibility studies 278 
 279 
2.6.1. Human keratinocyte cell cultures 280 
HaCaT, a long-term cell line of human keratinocytes immortalized from a 62-year old Caucasian male 281 
donor (Boukamp et al., 1988), was used for the assessment of Vm and VmLNB biocompatibility. Cells 282 
were grown as adherent monolayers in DMEM medium supplemented with 10% fetal bovine serum, 283 
100 U/mL penicillin, 100 µg/mL streptomycin and 2 mM L-glutamine in a humidified CO2/air-284 
incubator at 37°C. Before starting the experiments, cells were washed with PBS, detached with 285 
trypsin/ethylenediaminetetraacetic acid (0.05/0.02 % v/v), washed with fresh medium and plated at a 286 
standard density (10
6
 cells/well in 6-well plates) in 2 mL of fresh medium. 287 
 288 
2.6.2. Vm and VmLNB cytotoxicity 289 
The potential cytotoxic effects of VmLNBs were measured as the release of lactate dehydrogenase 290 
(LDH) from HaCaT cells into the extracellular medium. Briefly, cells were incubated in DMEM 291 
medium for 24 h with/without 1 mg/mL Vm, either free or carried by VmLNBs, in a humidified 292 
CO2/air-incubator at 37°C. Then, 1 mL of cell supernatants was collected and centrifuged at 12000 293 
rpm13000g for 2 min. Cells were washed with fresh medium, detached with 294 
trypsin/ethylenediaminetetraacetic acid (0.05/0.02 % v/v), washed with PBS, resuspended in 1 mL of 295 
TRAP (82.3 mM triethanolamine, pH 7.6), and sonicated on ice with a 10 s burst. 5 microL of cell 296 
lysates and 50 microL of cell supernatants were diluted with TRAP and supplemented with 0.5 mM 297 
sodium pyruvate and 0.25 mM NADH (300 microL as a final volume) to start the reaction. The 298 
reaction was followed measuring the absorbance at 340 nm (37 °C) with Synergy HT microplate 299 




NADH/min/well. Finally, cytotoxicity was calculated as the net ratio between extracellular and total 301 
(intracellular + extracellular) LDH activities. 302 
 303 
2.6.3. Human keratinocyte cell viability 304 
Cell viability was evaluated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 305 
(MTT) assay. HaCaT cells were incubated for 24 h with/without 1 mg/mL Vm, either free or carried by 306 
VmLNBs, in a humidified CO2/air-incubator at 37°C. Thereafter, 20 microL of 5 mg/mL MTT in 307 
PBS were added to cells for 3 additional hours at 37 °C. The plates were then centrifuged, the 308 
supernatants discarded and the dark blue formazan crystals dissolved using 100 μL of lysis buffer 309 
containing 20 % (w/v) sodium dodecyl sulfate, 40 % N,N-dimethylformamide (pH 4.7 in 80 % acetic 310 
acid). The plates were then read on Synergy HT microplate reader at a test wavelength of 550 nm and 311 
at a reference wavelength of 650 nm. 312 
 313 
2.7. Microbiological assays 314 
 315 
2.7.1. Determination of vancomycin antimicrobial activity against MRSA 316 
Vm solutions were freshly prepared for each experiment. Determination of the minimum inhibitory 317 
concentration (MIC) of vancomycin was carried by the microdilution broth method according to the 318 
latest Clinical and Laboratory Standards Institute (CLSI) guidelines (CLSI 2012). Interpretation of the 319 
results was performed as outlined in the above mentioned CLSI guidelines (CLSI 2012). 320 
 321 
2.7.2. In vitro antibacterial efficiency of VmLNBs against MRSA.  322 
MRSA, isolated from human ulcerated wounds (Infermi Hospital, Biella, Italy), was cultured over 323 




min centrifugation at 4,000 rpm, diluted in TSB to 10
4
 colony-forming-unit (CFU)/mL, as confirmed 325 
by colony counts on TSA, and then incubated in TSB with VmLNBs, loaded with Vm at different 326 
concentrations (1, 0.1, 0.01, and 0.004 mg/mL), in sterile sampling tubes for 2, 3, 4, 6, and 24 hours at 327 
37°C. Controls represented by either bacteria incubated in TSB, bacteria incubated with blank NBs or 328 
bacteria incubated in the presence of free Vm at different concentrations (1, 0.1, 0.01 and 0.004 329 
mg/mL), were also performed. At each incubation time, serial 10-fold dilutions in saline solution (0.9% 330 
NaCl) were prepared from each sample, and 100 microL of each dilution were spread on TSA, so that 331 
the number of CFU/mL could be determined. 332 
 333 
2.7.3. Imaging with confocal laser scanning microscopy 334 
MRSA bacteria S. aureus strain werewas grown in TSB at 37°C in agitation until reaching the 335 
concentration of 1x10^
9
 CFU/mL. Then, 1 mL aliquot of bacteria was pelleted (3000g x 10 min at 336 
4°C), resuspended in PBS 1x and incubated with 6-coumarin-labeled VmLNBs, 6-coumarin-labeled 337 
NBs, or FITC-labeled Vm at a dilution of 1:11, as for previous experiments performed on eukaryotic 338 
cells. Each sample was placed on orbital shaker (160 rpm) in the dark at 37°C for 2h and 4h. After 339 
incubation, one drop from each suspension was streaked on poly-L-lysine-coated microscope slides and 340 
allowed to dry. Then, bacteria were stained with iodide propidium (PI) in PBS 1X and again allowed to 341 
dry. Fluorescence images were taken with an Olympus IX70 inverted laser scanning confocal 342 
microscope, and captured using FluoView 200 software. 343 
 344 
2.8. Statistical analysis 345 
At least three independent experiments, each one in duplicate or triplicate, were performed for every 346 
investigational study. Numerical data are shown as means ± SEM for inferential results or as means ± 347 




as representative pictures. All data were analyzed by a one-way Analysis of Variance (ANOVA) 349 
followed by Tukey's post-hoc test (software: SPSS 16.0 for Windows, SPSS Inc., Chicago, IL). P<0.05 350 





3. Results  353 
 354 
3.1. Characterization of VmLNB and control (blank NB and Vm) formulations 355 
Before NB production, the interaction between dextran sulfate and Vm was firstly investigated to 356 
optimize Vm/dextran sulfate ratio. Results indicated that Vm was complexed at 99% by dextran sulfate 357 
solution until the concentration of 0.5 mg/mLl (data not shown). The Vm/dextran sulfate ratio was 358 
calculated corresponding to 2:1 (w/w). Based on this preliminary information, NBs were prepared 359 
according to the protocol described in the Materials and Methods section. After manufacturing, 360 
VmLNB and blank NB formulations (with or without 6-coumarin in the inner core) were characterized 361 
physico-chemically. Results are shown in Figure 2 and Tables 1-2. Both VmLNBs and NBs displayed 362 
spherical shapes with a core-shell structure by TEM analyses. All sizes were in the nanometer range, 363 
with all formulations displaying around 300 nm as a value for average diameters. All polidispersity 364 
indexes were included between 0.22 and 0.25. Zeta potentials ranged from -34 mV (NBs) to -29 mV 365 
(VmLNBs). The loading of Vm in the NB structure did not significantly affect the viscosity of the 366 
formulations. NB viscosity (1.12 cP) was slightly increased upon binding with Vm (1.25 cP for 367 
VmLNBs). NBs were able to load Vm with an encapsulation efficiency of 86% and loading capacity of 368 
29%.  369 
 370 
3.2. Stability of VmLNB and control (blank NB and Vm) formulations 371 
NB and VmLNB formulations proved to be physically stable over time, as confirmed by long-term 372 
checking of the parameters assessed in the previous paragraph. Indeed, the obtained values did not 373 
remarkably change up to six months after the manufacturing of the formulations stored at 4 °C (data 374 
not shown). Furthermore, the chemical stability of the drug was comparatively checked between free 375 




temperatures (25°C and 37°C). As shown in Figure 3, the drug Vm always resulted much more stable 377 
from a chemical point of view when properly incorporated in the nanocarriers (VmLNBs) than as such 378 
in solution.alone. 379 
 380 
3.3. Human biocompatibility 381 
 382 
The potential toxicity of Vm solution and VmLNB suspension on human skin cells was assessed by 383 
testing in vitro cultured HaCaT keratinocytes. Cells were incubated for 24 h alone, with 10% v/v Vm 384 
solution, or with VmLNB nanosuspensions in normoxic conditions (20% O2). Thereafter, cytotoxicity 385 
was analyzed by LDH assay, and cell viability by MTT assay. As shown in Figure 4, neither Vm nor 386 
VmLNBs did show significant toxic effects and HaCaT cell viability was not significantly affected by 387 
either formulation.  388 
 389 
3.4. In vitro drug release from VmLNBs 390 
In vitro drug release from VmLNB nanosuspension and free Vm solution were comparatively 391 
evaluated over time. As shown in Figure 5 (time course studies up to 6 h) and Table 23 (end-point data 392 
up to 24 h), 1 mg/mL Vm release from VmLNBs was slow and prolonged over time, compared to free 393 
drug solution diffusion. No initial burst effect was observed indicating Vm incorporation in NB shell. 394 
Further information on additional incubation times and drug concentrations for VmLNBs is available in 395 
Supplementary Materials (Table S31). Vm/VmLNB drug release ratios at different times (2, 3, 4, 6, 396 
and 24 h) were also calculated (see Table 23), in order to allow normalization of the results from 397 
treatment with VmLNBs in the microbiological experiments described in the following paragraph. 398 
 399 




According to preliminary microbiological analyses performed on the MRSA strain employed in the 401 
present experiments, 0.004 mg/mL resulted as the MIC value for Vm. Therefore, decreasing Vm 402 
concentrations from 1 mg/mL (used for the studies described in the previous paragraphs) to 0.004 403 
mg/mL (MIC value) were employed in a series of experiments aimed at comparatively evaluating Vm 404 
(either free or carried by VmLNBs) antibacterial effectiveness against MRSA. Bacteria were incubated 405 
at different times (2, 3, 4, 6, and 24 h) either alone (ctr) or with free Vm, VmLNBs, or blank NBs. The 406 
initial drug concentrations (1; 0.1; 0.01; and 0.004 mg/mL) loaded on VmLNBs were the same as those 407 
solved in free Vm solution. However, as emerged in the previous paragraph, drug release from 408 
VmLNBs is significantly slower than free Vm solution diffusion. For this reason, before proceeding 409 
with the analysis of the results, all values on bacterial growth referring to Vm- and VmLNB-treated 410 
samples were normalized upon time-dependent Vm/VmLNB drug release ratios shown in Table 23. 411 
Normalized results are shown in Figure 6, whereas raw data are available in Supplementary Materials 412 
(Figure S21). 1 mg/mL Vm effectively inhibited bacterial growth at all times, independently from 413 
being free or carried by the nanocarrier. Lower drug concentrations of free Vm solution were effective 414 
against MRSA only after longer times of incubation (at least 3 h for 0.1 mg/mL and 0.01 mg/mL Vm; 415 
and at least 4 h for 0.004 mg/mL Vm). Interestingly, Vm antibacterial efficacy was significantly 416 
improved when the drug was carried by VmLNBs. Indeed, VmLNB-dependent inhibition of bacterial 417 
growth was significantly enhanced compared to free Vm solution, at all drug concentrations. 418 
Additionally, compared to free Vm solution, VmLNB antibacterial effects appeared earlier, as they 419 
were already evident after 2 h of incubation (the first time-point of the observational period) at all Vm 420 
concentrations. Blank NBs did not show any antibacterial activity.  421 
Further analysis by confocal microscopy (Figure 7) displayed that MRSA avidly internalized free 422 
fluorescent Vm already after 2 h of incubation, but not fluorescent VmLNBs. Fluorescent Vm-free NBs 423 




3.6. US-triggered drug permeation 425 
The ability of US to promote Vm permeation through the skin was assayed by employing a purposely 426 
modified Franz cell constituted by a donor and a recipient chamber separated by a pig skin layer (see 427 
Figure 8A for a schematic representation of the apparatus). As shown in Figure 8B, the administration 428 
of US (t = 10 min; f = 2.5 MHz; P = 5 W) strongly induced VmLNBs to deliver the antibiotic drug 429 
from the donor chamber throughout the pig skin membrane into the recipient chamber up to 6 h. 430 
Furthermore, drug accumulated in the skin after US treatment reached 158 g/cm
2 








4. Discussion 436 
 437 
Vm currently represents the main stay against MRSA infections (Koyama et al., 2013; Kullarrrant et 438 
al., 2016). However, Vm administration raises several issues that urgently need to be faced, including 439 
its marked instability, low oral bioavailability, complex concentration-time profile, low tissue 440 
penetration (ranging from 10% in diabetic to 30% in normal skin and soft tissues), and several adverse 441 
effects (Mawhinney et al., 1992; Raverdy et al., 2013; Vandecasteele et al., 2012; Vidal et al., 1992; 442 
Giandalia et al., 2001). In the attempt to counteract these drawbacks, thus improving the effectiveness 443 
of Vm delivery, some novel nanocarriers have been developed: i) Vm coupling to chitosan as an ocular 444 
drug delivery vehicle for topical use in rabbit eyes has appeared more effective than carrier-free Vm 445 
(Khangtragool et al., 2011); ii) PEGylated liposomal Vm enhanced the effective treatment of MRSA 446 
pneumonia and simultaneously reduced the nephrotoxicity risk compared with conventional and non-447 
PEGylated Vm formulations (Muppidi et al., 2011); iii) Vm-loaded liposomes, stabilized with chitosan 448 
modified gold nanoparticles bounded to their surface, have proven effective in inhibiting the bacterial 449 
growth (Pornpattananangkul et al., 2011); and iv) Vm-containing trehalose and hydroxyethylcellulose 450 
spherical matrices have been developed as new delivery systems suitable for topical applications on 451 
extensive and purulent wounds (Giandalia et al., 2001). Recently, Vm-loaded polymersosomes were 452 
developed from a novel pegylated oleic acid polymer for sustained antibiotic delivery (Omolo et al., 453 
2017). Overall, these works represent the proof-of-principle for the feasibility of choice of nanocarriers, 454 
as alternative drug delivery systems to obtain the desired drug release rates and bioavailability 455 
(Kalhapure et al., 2015). However, the effectiveness of those nanocarriers was seriously undermined by 456 
their poor ability to cross the stratum corneum, a skin barrier displaying low permeability unless proper 457 




For these reasons, the present study aimed at developing Vm nanocarriers as a new platform to be 459 
effectively and safely employed for Vm topical administration to treat wound infections. To this 460 
purpose, NBs with core-shell nanostructures were identified as first choice carriers due to their known 461 
benefits in association with drug delivery, including small size, stability, suitability for drug loading, 462 
responsiveness to external stimuli such as US, and controlled drug release abilities (Marano et al., 463 
2016; Cavalli et al., 2009a; Cavalli et al., 2009b; Cavalli et al., 2016). In this study, dextran sulfate was 464 
chosen as main constituent of the polysaccharidic shell as a consequence of the large amount of data 465 
from the literature supporting dextran biocompatibility (Bos et al., 2005; De Groot et al., 2001). 466 
Encouragingly, dextran-based hydrogels have already been employed as matrices in tissue engineering, 467 
without showing signs of inflammation in vivo (Möoller et al., 2007), and recent toxicological studies 468 
have shown that dextran, as well as the products from its mechano-chemical processing, can be 469 
classified as class 4 (low-toxicity) substances (Dushkin et al., 2013). Moreover, dextran sulfate presents 470 
a negative charge that can electrostatically interact with the positive charged Vm. On the other hand, 471 
PFP was employed as principal constituent of the inner core, since it is the most widely used 472 
fluorocarbon in oxygenating emulsions and NB formulations (Cabrales and Intaglietta, 2013, Castro 473 
and Briceno, 2010). In order to load Vm, dextran sulfate-shelled/PFP-cored NBs were then 474 
functionalized by exploiting the electrostatic interactions occurring between the negatively charged 475 
sulfate groups of the shell and the protonated amino groups of the drug. The obtained VmLNBs 476 
displayed a spherical shape and a well-defined core-shell structure with a polymeric shell thickness of 477 
about 40 nm, average diameters of 300 nm,  viscosity of 1.25 cP, and negatively charged surfaces. Of 478 
note, the observed decrease of zeta potential values of ~ 15 % for VmLNBs (around -29 mV) with 479 
respect to blank NBs (around -34 mV) confirmed the occurrence of electrostatic interactions between 480 




charge neutralization of the bubble surface and allowing a good Vm encapsulation efficiency (86%) 482 
and loading capacity (29%) in the NB systems.  483 
In addition, it should be noticed that since the zeta potential measures charge repulsion or attraction 484 
between particles, it represents a fundamental parameter to avoid nanoparticle aggregation, with zeta 485 
potentials lower than -25 mV or larger than +25 mV being generally required for physical stability of 486 
colloid systems (Shah and Eldridge, 2014). The stability of VmLNB formulations was further 487 
confirmed by long-term checking of their size, surface charge, and viscosity values, which did not 488 
show any significant changes up to six months after manufacturing, stored at 4 °C. On the other hand, 489 
drug stability was comparatively checked between free Vm solution and VmLNB suspension either 490 
over time (up to 14 days) or at different temperatures (25°C and 37°C), revealing an increased stability 491 
for Vm when properly encapsulated in the nanocarriers. This appears as an undoubtedly advantageous 492 
feature for VmLNB formulations, since they might prove useful to overcome the reported instability of 493 
Vm in aqueous solutions at body temperature (Mawhinney et al., 1992, Raverdy V et al., 2013). 494 
Interestingly, VmLNBs displayed a slow and prolonged drug release kinetics compared to Vm aqueous 495 
solution, with only 16% of the drug being released from VmLNBs after 6 h. These data support the 496 
hypothesis that VmLNBs may be employed as an effective drug reservoir until reaching the target site, 497 
where the antibiotic would be released upon sonication at an appropriate moment only. The features of 498 
VmLNBs might be exploited for the design of innovative wound dressing following their inclusion in 499 
polymeric base. Indeed, NBs can be dispersed in polymer gel without changing physico-chemical 500 
characteristics, as previously showed (Prato et al., 2015). Another intriguing feature of VmLNBs relies 501 
on the reported evidence that surface charges play a pivotal role in making a nanoparticle suitable for 502 
topical treatment, since they enhance its interaction with the skin and improve its therapeutic effect on 503 
inflamed cutaneous tissues, either without (Abdel-Mottaleb et al., 2012) or with concomitant US 504 




treatment due to the anionic nature of the skin (Wu et al., 2010), some authors have shown that anionic 506 
nanoparticles can be more effective (Lee et al., 2013) and less toxic (Ryman-Rasmussen et al., 2007) 507 
than the cationic ones. These latter data appear  consistent with our results through investigation by 508 
biochemical assays to assess VmLNB biocompatibility with human skin tissues. Indeed, VmLNBs did 509 
not induce any in vitro cytotoxic effects on HaCaT keratinocytes, a skin cell line that was originally 510 
immortalized from a 62-year old donor (Boukamp et al., 1988). This peculiar information strengthens 511 
remarkably the evidence on VmLNB safety for future topical applications. 512 
VmLNB and carrier-free Vm antimicrobial activity against MRSA were comparatively investigated, 513 
also analyzing Vm and NB physical interaction with the bacterial cell wall by confocal microscopy.  514 
Interestingly, VmLNBs were more effective in MRSA bacterial growth inhibition then free Vm, 515 
promoting enhanced and earlier antibacterial effects, although they were not internalized by bacteria, 516 
opposite to free Vm. This behavior appears to be a likely consequence of time-sustained release of Vm 517 
from VmLNBs. 518 
Notably, an important issue that requires caution while evaluating the feasibility for any topical drug 519 
treatment is represented by the considerably low degree of permeability of the skin, the primary 520 
defense system for the body. This organ consists of several layers, including the stratum corneum, the 521 
epidermis, and the dermis. In particular the stratum corneum - composed of corneocytes interspersed in 522 
a laminate of compressed keratin and intercorneocyte lipid lamellae - is very poorly permeable to 523 
foreign molecules and represents the main obstacle to transdermal drug delivery (Naik et al., 2000). 524 
However, an ideal antibiotic drug formulation should be efficiently localized in the epidermis/dermis 525 
and provide a sustained drug release over time (Prabhu et al., 2012). To allow a drug to penetrate the 526 
skin, several approaches have been proposed, including skin patches, ionophoresis, chemical 527 




Interestingly, antimicrobial properties have been reported for US, although its effectiveness strongly 529 
varies depending on the targeted type of pathogen (fungi vs bacteria; cocci vs bacilli; Gram-positive vs 530 
Gram-negative) (Sango et al., 2014). Furthermore, synergistic effects between US and antibiotics have 531 
been reported in a series of studies: i) antibiotic treatment coupled with US irradiation resulted in 532 
enhanced bactericidal activity against both Gram-positive and Gram-negative bacteria, especially for 533 
aminoglycosides (Yu et al., 2012); ii) the combination of Vm and US decreased S. aureus viable counts 534 
by two orders of magnitude compared to Vm alone (Ayan et al., 2008); and iii) the addition of NB-535 
enhanced US to doxycycline treatment improved the drug effectiveness in eradicating intracellular 536 
Chlamydia trachomatis (Ikeka-Dantsuji et al., 2011). US-dependent enhancement of antibiotic action 537 
on biofilms wa      d      ‘      u      ff   ’  I         g    V       f    h  ugh S. epidermidis 538 
biofilms was shown to be significantly enhanced by US, with bubbles being able to increase the biofilm 539 
permeability to Vm (Dong Y. et al., 2013).  540 
As discussed previously, VmLNBs can be effectively employed as an important reservoir to store the 541 
drug until trespassing the stratum corneum of the skin  and reaching the target site. In order to achieve 542 
the latter goal, US was assayed for its ability to induce VmLNBs to trespass an in vitro cutaneous layer, 543 
thereby releasing Vm throughout the skin. Notably, the skin from the pig ear is widely recognized as a 544 
good model for human skin permeability, since it displays human-like histological and physiological 545 
properties, including epidermal thickness and composition, dermal structure, lipid content and general 546 
morphology (Dick and Scottet al., 1992). The validity of the porcine model has been established by 547 
comparing the permeability of simple marker molecules with the corresponding values across human 548 
skin (Herkenne et al., 2006, Sekkat et al., 2002). Therefore, the porcine ear skin represents so far the 549 
most accountable in vitro model to mimic the human skin in studies on percutaneous penetration 550 
(Jacobi et al., 2007). In our experiments, US appeared essential to promote Vm release from VmLNBs 551 




the passive transport of free vancomycin hydrochloride was negligible, being a charged and hydrophilic 553 
molecule. The amount of Vm accumulated in the skin after US application combined with NBs was 554 
greater than MIC value. 555 
 556 
5. Conclusions 557 
In the present work, dextran sulfate-shelled and PFPperfluoropentane-filled NBs were developed for 558 
Vm delivery. VLNBs proved to be effective in MRSA bacterial killing without showing toxic effects 559 
on human keratinocytes. The combination of NBs and US enhanced Vm permeation through pig skin 560 
and promoted drug skin accumulation. Based on these results, Vm topical administration through 561 
proper NB formulations might be a promising strategy for the local treatment of MRSA skin infections.  562 
The study represents the proof of concept for the future development of advanced multifunctional 563 
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Figure legends 832 
 833 
Figure 1. Schematic structure of VmLNB formulations. Vm nanocarriers described in the present 834 
work display a core-shell structure. PFP was employed as core fluorocarbon, whereas dextran sulfate 835 
was chosen as polysaccharidic shell molecule. Vm was inserted into the outer shell throughout dextran 836 
sulfate chains. In selected experiments, VmLNBs were further functionalized by including fluorescent 837 
6-coumarin in the inner core. 838 
 839 
Figure 2. NB and VmLNB morphology. NBs and VmLNBs were checked for morphology by TEM. 840 
Results are shown as representative images from three different preparations. Panel A. NB image by 841 
TEM. Panel B. VmLNB image by TEM. (see also Figure S1 in Supplementary Materials for additional 842 
images of multiple nanobubbles within the same field). 843 
 844 
Figure 3. Stability of Vm and VmLNB formulations. The stability of Vm solution and VmLNB 845 
suspension was monitored up to 14 days either at room temperature (Panel A) or at 37°C (Panel B) 846 
through analysis by HPLC. Results are shown as means ± SD from three different preparations for each 847 
formulation. Data were also analyzed for significance by ANOVA. Versus Vm solution: * p<0.001. 848 
 849 
Figure 4. Biocompatibility of Vm and VmLNBs with  human keratinocytes in vitro. HaCaT cells 850 
(10
6
 cells/2 mL DMEM medium implemented with 10% FCS) were left untreated (ctr) or treated with 851 
200 microL of Vm solution or VmLNB suspension for 24 h in normoxia (20% O2). Thereafter, Vm 852 
and VmLNB cytotoxicity were measured through LDH assay (Panel A), whereas cell viability was 853 




experiments. Data were also evaluated for significance by ANOVA. No significant differences were 855 
found among all conditions. 856 
Figure 5. In vitro Vm release from Vm and VmLNB formulations. Vm release from Vm solution 857 
and VmLNB suspension was monitored up to 6 h. Results are shown as means ± SD from three 858 
different preparations for each formulation. Data were also analyzed for significance by ANOVA. 859 
Versus Vm solution: * p<0.001.  860 
 861 
Figure 6. Antibacterial activity of Vm and VmLNBs against MRSA. MRSA were left for 2, 3, 4, 6 862 
and 24 hours at 37°C alone (ctr) or incubated with 10% v/v NBs or different concentrations of Vm, 863 
either free or loaded on VmLNBs (Panel A: 1 mg/mL; Panel B: 0.1 mg/mL; Panel C: 0.01 mg/mL; 864 
Panel D: 0.004 mg/mL). Results are shown as means ± SEM from three independent experiments. Data 865 
on Vm- and VmLNB-treated samples were normalized upon Vm/VmLNB release ratios reported in 866 
Table 23 (see also in Supplementary Materials: Table S31 for further information on percentages of 867 
drug release from VmLNBs at different times/concentrations; and Figure S21 for raw data on VmLNB 868 
antibacterial effects). All data were also evaluated for significance by ANOVA. Versus ctr: * p < 0.02; 869 
versus Vm: ° p < 0.05.  870 
 871 
Figure 7. Drug loading on dextran sulfate-shelled NBs prevents Vm internalization by MRSA. 872 
MRSA were left alone or incubated with 10% v/v 6-coumarin-labeled VLNBs, 6-coumarin-labeled 873 
NBs, and FITC-labeled Vm for 2h at 37°C. After staining bacteria with PI, confocal fluorescent images 874 
were taken using FITC and TRITC filters. Data are shown as representative images from three 875 





Figure 8. US-triggered sonophoresis of VmLNBs through skin membranes. US (t = 10 min; f = 2.5 878 
MHz; P = 5 W) abilities to induce sonophoresis and Vm permeation from VmLNBs were evaluated up 879 
to 6 h by using a vertical diffusion Franz cell consisting in two chambers (donor and recipient, 880 
respectively) separated by a pig skin layer (see scheme in Panel A). Results are shown in Panel B as 881 
means ± SD from three independent experiments. Data were also evaluated for significance by 882 




Tables and legends 884 
 885 
Formulation Average diameter 
± SD (nm) 
Polydispersity  
index 
Zeta Potential  
± SD (mV) 
Viscosity 
(cP) 
NBs 313.4 ±  26.4 0.24 ± 0.02 - 34.5 ± 0.38 1.22 
VmLNBs 304.6 ± 14.6 0.22 ± 0.03 - 28.6 ± 1.34 1.25 
Fluorescent NBs 312.8 ±  22.7 0.25 ± 0.02 - 34.1 ± 1.22 1.24 
Fluorescent VmLNBs 308.9 ± 22.4 0.23 ± 0.01 - 29.5 ± 1.88 1.23 
 886 
Table 1. Physical-chemical characterization of NBbs and VmLNBs. Liquid formulations were 887 
characterized for average diameters, polydispersity index, and zeta potential by light scattering. The 888 
viscosity (cP) of NB and VmLNB suspensions was determined at 25 °C by using a Ubbelohde capillary 889 
viscosimeter. Results are shown as means ± SD from three preparations. See also Figures 1-2 for 890 
further detail on NB and VmLNB structure and morphology. 891 
 892 
Sample solution Viscosity  (cP) 




Table 2. Viscosity of Vm solution, NB, and VmLNB suspensions. The viscosity (cP) of NB and 894 
VmLNB suspensions as well as free Vm solution was determined at 25 °C by using a Ubbelohde 895 









% drug release from 
Vm solution 
% drug release  
from VmLNBs 
Vm/VmLNB 
drug release ratio 
2 36.57 5.99 6.11 
3 45.97 7.97 5.78 
4 57.16 10.27 5.57 
6 73.44 14.59 5.03 
24 92.34 35.84 2.58 
 899 
Table 23. In vitro drug release from Vm solution and VmLNB suspension. After incubation for 900 
increasing times (first column), the percentages of in vitro drug release from Vm solution (second 901 
column) and VmLNB suspension (third column) were measured. Then, Vm/VmLNB drug release 902 
ratios (fourth column) were calculated for each time considered.  All incubation times (2, 3, 4, 6, and 903 
24 h) were purposely chosen to further normalize the results from the experiments with MRSA (see 904 
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